



# CANCER REPORT



2022



**Ramathibodi Comprehensive Cancer Center**

Faculty of Medicine Ramathibodi Hospital

Mahidol University, Bangkok Thailand

ISBN (e-book): 978-616-443-860-6



# **RAMATHIBODI CANCER REPORT**

**2022**

**Ramathibodi Tumor Registry: A subsidiary of  
Ramathibodi Comprehensive Cancer Center**

**Faculty of Medicine, Ramathibodi Hospital**

**Mahidol University**

## TABLE OF CONTENT

<b>INTRODUCTION .....</b>	<b>III</b>
<b>ACKNOWLEDGEMENTS.....</b>	<b>IV</b>
<b>Ramathibodi Hospital Cancer Committee, 2022.....</b>	<b>V</b>
<b>Ramathibodi Hospital Cancer Registry Committee, 2022 .....</b>	<b>VI</b>
<b>CHAPTER I.....</b>	<b>1</b>
<b>REGISTRY PROCEDURE AND STATISTICAL METHODS.....</b>	<b>1</b>
1.1 Purpose of the registry .....	1
1.2 Data collection.....	1
1.3 Statistical Methods.....	2
<b>CHAPTER II .....</b>	<b>3</b>
<b>OVERALL CANCERS.....</b>	<b>3</b>
Table 2.1 Number of patients. ....	3
Table 2.2 Most valid method of diagnosis.....	4
Table 2.3 Number of cancer cases by staging of present extent of disease. ....	5
Table 2.4 Number of cancer cases by age and sex, 2022.....	6
<b>CHAPTER III.....</b>	<b>7</b>
<b>TEN LEADING SITES OF CANCER, 2022.....</b>	<b>7</b>
Table 3.1 Ten leading sites of cancer in both sexes. ....	7
Table 3.2 Ten leading sites of cancer in male.....	8
Table 3.3 Ten leading sites of cancer in female.....	9
Table 3.4 Site of cancer in childhood by ICCC, age<18, both sexes.....	10
<b>CHAPTER IV .....</b>	<b>11</b>
<b>RAMATHIBODI CANCER REGISTRY .....</b>	<b>11</b>
Table 4.1 Annual report .....	11
Table 4.2 Percentage of morphologically verified and death certificate only cases...	13
Table 4.3 Number of cancer cases by site, sex and age. ....	15
Table 4.4 Number of cancer cases by primary site. ....	21
Table 4.5 Number of cancer cases by pathology according to site. ....	27
<b>CHAPTER V .....</b>	<b>48</b>
<b>THE MOST COMMON CANCER SITES .....</b>	<b>48</b>
Breast .....	49
Colorectal.....	51
Bronchus and Lung .....	53
Prostate gland.....	55
Liver and Intrahepatic bile duct .....	57
Hematopoietic and Reticuloendothelial.....	59
Thyroid gland.....	61
Childhood Cancer .....	63
<b>CHAPTER VI.....</b>	<b>65</b>
<b>DISTRIBUTION BY REGIONAL OF THAILAND .....</b>	<b>65</b>


## INTRODUCTION

Ramathibodi Cancer Report 2022 is the result of the fruitful collaboration between units and departments of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University.

I would like to thank all of our collaborators for their help in providing data presented in this volume of Cancer Report.

Ramathibodi tumor registry provides the hospital-based cancer data of new cancer cases each year. This data provides important base information in the field of research and policy making.

I hope that the data from this Ramathibodi Cancer Report will benefit health personals, physicians, medical students, researchers, patients, relatives and eventually general population.



**Associate Professor Surasak Leelaudomlipi**

Director of Ramathibodi Hospital

Faculty of medicine, Ramathibodi Hospital

Mahidol University

## ACKNOWLEDGEMENTS

**We would like to express our gratitude to:**

The dean of Faculty of Medicine Ramathibodi Hospital, Professor Piyamitr Sritara, for his support and providing resources for this Cancer Registry.

The director of Ramathibodi Hospital, Associate Professor Surasak Leelaudomlapi for all his support and advise.

The former chairman of Ramathibodi Comprehensive Cancer Center Committee; Associate Professor Ekaphop Sirachainan for all his support and advise in preparing this report.

The Ramathibodi Comprehensive Cancer Center Committee members and Cancer Registry Committee members for their hard work in contribution to the preparation of the Cancer Registry manuscript.

Cancer Registry staffs of the Faculty of Medicine, Ramathibodi Hospital for their continuous support in the data collection.

Finally, we would like to give a special thanks to the cancer registry coordinator and her team who have pushed their maximum efforts in contribution to the good quality cancer data.



**Professor Sarikapan Wilailak**

Chairman, Cancer Registry Committee  
Ramathibodi hospital, Mahidol University



## Ramathibodi Hospital Cancer Registry Committee, 2022

### CHAIRMAN:

Prof. Sarikapan Wilailak, M.D. Department of Obstetrics and Gynecology

### COMMITTEE:

Prof. Suradej Hongeng, M.D. Department of Pediatrics

Assoc. Prof. Ekaphob Sirachainan, M.D. Department of Medicine

Assoc. Prof. Arb-Aroon Lertkhachonsuk, M.D. Department of Obstetrics and Gynecology

Assoc. Prof. Panuwat Lertsithichai, M.D. Department of Surgery

Assoc. Prof. Sansanee Wongwaisayawan, M.D. Department of Pathology

Asst. Prof. Chomporn Sitathanee, M.D. Department of Radiology

Panus Binsirawanich, M.D. Department of Otolaryngology

### COMMITTEE AND SECRETORY:

Nintita Sripaiboonkij Thokanit, Dr.Ph Ramathibodi Comprehensive Cancer Center

### TUMOR REGISTRY TEAM:

Nintita Sripaiboonkij Thokanit, Dr.PH Medical Statistics

Sopit Promchana Medical Statistics

Tanapol Thonkamdee Medical Statistics

Phonsuda Jitkasikorn Medical Statistics

Saruta Bubphapasom Medical Statistics

Jakkapong Pongsachai Technical Information

Chanpen Preedee General Affairs Officer

Pisamai Srinaka High Vocational Certificate

# CHAPTER I

## REGISTRY PROCEDURE AND STATISTICAL METHODS

### 1.1 Purpose of the registry

The Ramathibodi Cancer Registry (RCR) is a hospital-based cancer registry. The epidemiology including incidence and survival data of all cancer patients who are diagnosed and/or treated for cancer in the Ramathibodi hospital are collocated. The goods of the RCR are to:

- Determine the incidence of cancer in Ramathibodi hospital with demographic and social characteristics.
- Evaluate the outcome including the survival and prognostic factors affecting the survival and mortality.
- Provide data in planning effectively plan services, measure prevention and intervention strategies.
- Provide a database and serve as a resource in conducting epidemiologic studies.
- Provide data to assist public health officers and hospital administrators in planning health policy.

### 1.2 Data collection

Each department in Ramathibodi hospital including surgical out patient, radiation outpatient and pathology laboratory is responsible to complete all data on cancer diagnosed and treated within six months of diagnosis. Sources for identifying eligible cases include:

- All types of malignancies including skin cancer, pre-invasive cancer or carcinoma in situ, neoplasm with malignant potential
- All types of myeloproliferative disorders
- All types of malignant histiocytosis
- Carcinomatosisperitonei without detectable primary
- Thymoma-both benign and malignant
- All type of CNS tumors (intracranial & spinal cord) both benign and malignant
- Gastrointestinal stomach tumor



#### Exclusion criteria

1. Pre-malignant

Remarks: When a cancer case is reported from more than one department, the information is consolidated into one record

#### **Reported cases contain the following data:**

- Patient characteristics (including demographic data at the time of cancer diagnosis)
- Descriptive data of cancer (including date of diagnosis, primary site\*, histology, metastatic sites, extent of disease, staging etc.)

\* Primary site, behavior, grade, and histology were coded

### **1.3 Statistical Methods**

#### **Morphologically verified cases (%MV):**

The percentage of cases whose diagnosis were based on cytology or histology examination of tissue from primary site or metastasis site, peripheral blood and bone marrow aspiration, including autopsy specimens.

#### **Childhood cancer:**


The results for cancer in the childhood are presented according to the diagnostic groups defined in "International Classification of Childhood Cancer 1996" this was done by simply adding together the cases in age between 0-18 years old

## CHAPTER II

### OVERALL CANCERS

**Table 2.1** Number of patients.


Type of patients	Male (Number, %)	Female (Number, %)	Total (Number, %)
One primary tumor	2,091 (99.9%)	2,755 (100.0%)	4,846 (99.9%)
Two primary tumor	3 (0.1%)	0 (0.0%)	3 (0.1%)
<b>Total</b>	<b>2,094</b>	<b>2,755</b>	<b>4,849</b>



**Figure 2.1** Number of patients.

**Table 2.2** Most valid method of diagnosis.


Basis of diagnosis	Number	%
Clinical investigation/imaging	109	2.3
Histology or metastasis	2	0.0
Histology of primary	4,738	97.7
<b>Total</b>	<b>4,849</b>	<b>100.0</b>



**Figure 2.2** Most valid method of diagnosis.

**Table 2.3** Number of cancer cases by staging of present extent of disease.


Staging	Male		Female		Total	
	Number	%	Number	%	Number	%
In situ	13	0.6	71	2.6	84	1.7
Localized	138	6.6	597	21.7	735	15.2
Regional LN	392	18.7	831	30.2	1,223	25.2
Distant metastasis	567	27.1	465	16.9	1,032	21.3
Recurrent	22	1.1	31	1.1	53	1.1
Unknown	962	45.9	760	27.6	1,722	35.5
<b>Total</b>	<b>2,094</b>	<b>100.0</b>	<b>2,755</b>	<b>100.0</b>	<b>4,849</b>	<b>100.0</b>



**Figure 2.3** Number of cancer cases by staging of present extent of disease.

**Table 2.4** Number of cancer cases by age and sex, 2022.

Age group	Male		Female		Both sexes	
	Number	%	Number	%	Number	%
0-4	28	1.3	23	0.8	51	1.1
5-9	11	0.5	10	0.4	21	0.4
10-14	9	0.4	15	0.5	24	0.5
15-19	9	0.4	12	0.4	21	0.4
20-24	16	0.8	11	0.4	27	0.6
25-29	14	0.7	39	1.4	53	1.1
30-34	32	1.5	84	3.1	116	2.4
35-39	44	2.1	130	4.7	174	3.6
40-44	55	2.6	176	6.4	231	4.8
45-49	85	4.1	195	7.1	280	5.8
50-54	144	6.9	296	10.7	440	9.1
55-59	202	9.7	294	10.7	496	10.2
60-64	313	15.0	359	13.0	672	13.9
65-69	352	16.8	377	13.7	729	15.0
70-74	316	15.1	303	11.0	619	12.8
75-79	234	11.2	193	7.0	427	8.8
80-84	142	6.8	135	4.9	277	5.7
85+	88	4.2	103	3.7	191	3.9
<b>Total</b>	<b>2,094</b>	<b>100.0</b>	<b>2,755</b>	<b>100.0</b>	<b>4,849</b>	<b>100.0</b>
<b>Mean</b>	<b>63.2</b>		<b>58.9</b>		<b>60.8</b>	
<b>S.D.</b>	<b>16.1</b>		<b>16.3</b>		<b>16.3</b>	




**Figure 2.4** Patient pyramids, 01/01/2022 - 31/12/2022

## CHAPTER III

## TEN LEADING SITES OF CANCER, 2022


**Table 3.1** Ten leading sites of cancer in both sexes.

Site	ICD-O	Number of cases	%
1. Breast	C50	886	18.3
2. Colon and Rectum	C18-C20	575	11.9
3. Trachea, Bronchus and Lung	C34	429	8.9
4. Prostate	C61	373	7.7
5. Liver and Intrahepatic Bile Ducts	C22	307	6.3
6. Hematopoietic and Reticuloendothelial	C42	280	5.8
7. Thyroid	C73	273	5.6
8. Skin	C44	223	4.6
9. Lymph nodes	C77	215	4.4
10. Urinary Bladder	C67	126	2.6
11. Other		1,162	23.9
<b>Total</b>		<b>4,849</b>	<b>100.0</b>

**Figure 3.1** Ten leading sites of cancer in both sexes. (%)

**Table 3.2** Ten leading sites of cancer in male.


Site	ICD-O	Number of cases	%
1. Prostate	C61	373	17.8
2. Colon and Rectum	C18-C20	314	15.0
3. Trachea, Bronchus and Lung	C34	224	10.7
4. Liver and Intrahepatic Bile Ducts	C22	205	9.8
5. Hematopoietic and Reticuloendothelial	C42	152	7.2
6. Lymph nodes	C77	109	5.2
7. Skin	C44	92	4.4
8. Urinary Bladder	C67	91	4.4
9. Kidney	C64	73	3.5
10. Nasopharynx	C11	46	2.2
11. Other		415	19.9
<b>Total</b>		<b>2,094</b>	<b>100.0</b>



**Figure 3.2** Ten leading sites of cancer in male. (%)

**Table 3.3** Ten leading sites of cancer in female.


Site	ICD-O	Number of cases	%
1. Breast	C50	884	32.1
2. Colon and Rectum	C18-C20	261	9.5
3. Thyroid	C73	228	8.3
4. Trachea, Bronchus and Lung	C34	205	7.4
5. Skin	C44	131	4.8
6. Hematopoietic and Reticuloendothelial	C42	128	4.7
7. Corpus Uteri	C54	125	4.5
8. Cervix Uteri	C53	109	4.0
9. Lymph nodes	C77	106	3.9
10. Liver and Intrahepatic Bile Ducts	C22	102	3.7
11. Other		476	17.3
<b>Total</b>		<b>2,755</b>	<b>100.0</b>

**Figure 3.3** Ten leading sites of cancer in female. (%)



**Table 3.4** Site of cancer in childhood by ICCC, age<18, both sexes.

Site	Male		Female		Total	
	Number	%	Number	%	Number	%
Leukemias - I	17	29.8	18	34.0	35	31.8
Lymphomas - II	9	15.8	4	7.5	13	11.8
Brain/CNS - III	6	10.5	7	13.2	13	11.8
Sympathetics NER - IV	7	12.3	4	7.5	11	10.0
Retinoblastoma - V	7	12.3	6	11.3	13	11.8
Renal - VI	1	1.8	0	0.0	1	0.9
Hepatic - VII	1	1.8	3	5.7	4	3.6
Malignant bone - VIII	0	0.0	2	3.8	2	1.8
Soft-tissue - IX	4	7.0	4	7.5	8	7.3
Germ cell - X	2	3.5	1	1.9	3	2.7
Carcinomas - XI	3	5.3	4	7.5	7	6.4
<b>Total</b>	<b>57</b>	<b>100.0</b>	<b>53</b>	<b>100.0</b>	<b>110</b>	<b>100.0</b>



\*ICCC: International Classification of Childhood Cancer.

**Figure 3.4** Site of cancer in childhood by ICCC, age<18, both sexes. (%)

## CHAPTER IV

### RAMATHIBODI CANCER REGISTRY

**Table 4.1** Annual report.

Site	Male		Female		Total		Site
	N	(%)	N	(%)	N	(%)	
Lip	1	0.0	3	0.1	4	0.1	C00
Base of Tongue	5	0.2	2	0.1	7	0.1	C01
Other and Unspecified Part of Tongue	22	1.1	11	0.4	33	0.7	C02
Gum	2	0.1	3	0.1	5	0.1	C03
Floor of Mouth	1	0.0	2	0.1	3	0.1	C04
Palate	5	0.2	3	0.1	8	0.2	C05
Other and Unspecified Part of Mouth	5	0.2	1	0.0	6	0.1	C06
Parotid gland	3	0.1	5	0.2	8	0.2	C07
Other and Unspecified Major Salivary Glands	0	0.0	2	0.1	2	0.0	C08
Tonsil	17	0.8	2	0.1	19	0.4	C09
Oropharynx	2	0.1	0	0.0	2	0.0	C10
Nasopharynx	46	2.2	14	0.5	60	1.2	C11
Pyriiform Sinus	7	0.3	0	0.0	7	0.1	C12
Hypopharynx	1	0.0	1	0.0	2	0.0	C13
Esophagus	31	1.5	5	0.2	36	0.7	C15
Stomach	36	1.7	47	1.7	83	1.7	C16
Small Intestine	2	0.1	9	0.3	11	0.2	C17
Colon	197	9.4	170	6.2	367	7.6	C18
Rectosigmoid Junction	19	0.9	14	0.5	33	0.7	C19
Rectum	98	4.7	77	2.8	175	3.6	C20
Anus and Anal Canal	2	0.1	3	0.1	5	0.1	C21
Liver and Intrahepatic Bile Ducts	205	9.8	102	3.7	307	6.3	C22
Gallbladder	3	0.1	6	0.2	9	0.2	C23
Other and Unspecified Part of Biliary Tract	9	0.4	9	0.3	18	0.4	C24
Pancreas	31	1.5	31	1.1	62	1.3	C25
Nasal Cavity and Middle Ear	8	0.4	5	0.2	13	0.3	C30
Accessory Sinuses	3	0.1	3	0.1	6	0.1	C31
Larynx	33	1.6	2	0.1	35	0.7	C32
Bronchus and Lung	224	10.7	205	7.4	429	8.8	C34
Thymus	5	0.2	8	0.3	13	0.3	C37
Heart, Mediastinum and Pleura	5	0.2	4	0.1	9	0.2	C38
Bones, Joints and Articular Cartilage of Limbs	4	0.2	2	0.1	6	0.1	C40

Site	Male		Female		Total		Site
	N	(%)	N	(%)	N	(%)	
Bones, Joints and Articular Cartilage of Other and Unspecified Sites	7	0.3	5	0.2	12	0.2	C41
Hematopoietic and Reticuloendothelial Systems	152	7.3	128	4.6	280	5.8	C42
Skin	92	4.4	131	4.8	223	4.6	C44
Peripheral Nerves and Autonomic Nervous System	0	0.0	1	0.0	1	0.0	C47
Retroperitoneum and Peritoneum	5	0.2	7	0.3	12	0.2	C48
Connective, Subcutaneous and Other Soft Tissues	23	1.1	30	1.1	53	1.1	C49
Breast	2	0.1	884	32.1	886	18.3	C50
Vulva	0	0.0	6	0.2	6	0.1	C51
Vagina	0	0.0	3	0.1	3	0.1	C52
Cervix Uteri	0	0.0	109	4.0	109	2.2	C53
Corpus Uteri	0	0.0	125	4.5	125	2.6	C54
Uterus	0	0.0	5	0.2	5	0.1	C55
Ovary	0	0.0	86	3.1	86	1.8	C56
Other and Unspecified Female Genital Organs	0	0.0	3	0.1	3	0.1	C57
Placenta	0	0.0	2	0.1	2	0.0	C58
Penis	6	0.3	0	0.0	6	0.1	C60
Prostate gland	373	17.8	0	0.0	373	7.7	C61
Testis	5	0.2	0	0.0	5	0.1	C62
Other and Unspecified Male Genital Organs	1	0.0	0	0.0	1	0.0	C63
Kidney	73	3.5	30	1.1	103	2.1	C64
Renal Pelvis	5	0.2	8	0.3	13	0.3	C65
Ureter	6	0.3	5	0.2	11	0.2	C66
Bladder	91	4.3	35	1.3	126	2.6	C67
Other and Unspecified Urinary Organs	2	0.1	0	0.0	2	0.0	C68
Eye and Adnexa	18	0.9	18	0.7	36	0.7	C69
Brain	24	1.1	28	1.0	52	1.1	C71
Spinal Cord, Cranial Nerves, And Other Parts of Central Nervous System	0	0.0	4	0.1	4	0.1	C72
Thyroid gland	45	2.1	228	8.3	273	5.6	C73
Adrenal gland	8	0.4	7	0.3	15	0.3	C74
Other Endocrine Glands and Related Structures	2	0.1	1	0.0	3	0.1	C75
Other and Ill-Defined Sites	1	0.0	1	0.0	2	0.0	C76
Lymph Nodes	109	5.2	106	3.8	215	4.4	C77
Unknown Primary Site	12	0.6	8	0.3	20	0.4	C80
<b>All Sites</b>	<b>2,094</b>	<b>100.0</b>	<b>2,755</b>	<b>100.0</b>	<b>4,849</b>	<b>100.0</b>	

**Table 4.2** Percentage of morphologically verified and death certificate only cases.

Site	Male		Female		Total		Site
	N	%MV	N	%MV	N	%MV	
Lip	1	100.0	3	100.0	4	100.0	C00
Base of Tongue	5	100.0	2	100.0	7	100.0	C01
Other and Unspecified Part of Tongue	22	100.0	11	100.0	33	100.0	C02
Gum	2	100.0	3	100.0	5	100.0	C03
Floor of Mouth	1	100.0	2	100.0	3	100.0	C04
Palate	5	100.0	3	100.0	8	100.0	C05
Other and Unspecified Part of Mouth	5	100.0	1	100.0	6	100.0	C06
Parotid gland	3	100.0	5	100.0	8	100.0	C07
Other and Unspecified Major Salivary Glands	0	0.0	2	100.0	2	100.0	C08
Tonsil	17	100.0	2	100.0	19	100.0	C09
Oropharynx	2	100.0	0	0.0	2	100.0	C10
Nasopharynx	46	97.8	14	100.0	60	98.3	C11
Pyriiform Sinus	7	100.0	0	0.0	7	100.0	C12
Hypopharynx	1	100.0	1	100.0	2	100.0	C13
Esophagus	31	100.0	5	100.0	36	100.0	C15
Stomach	36	100.0	47	100.0	83	100.0	C16
Small Intestine	2	100.0	9	100.0	11	100.0	C17
Colon	197	100.0	170	100.0	367	100.0	C18
Rectosigmoid Junction	19	100.0	14	100.0	33	100.0	C19
Rectum	98	99.0	77	100.0	175	99.4	C20
Anus and Anal Canal	2	100.0	3	100.0	5	100.0	C21
Liver and Intrahepatic Bile Ducts	205	66.8	102	77.5	307	70.4	C22
Gallbladder	3	100.0	6	83.3	9	88.9	C23
Other and Unspecified Part of Biliary Tract	9	100.0	9	88.9	18	94.4	C24
Pancreas	31	93.6	31	90.3	62	91.9	C25
Nasal Cavity and Middle Ear	8	100.0	5	100.0	13	100.0	C30
Accessory Sinuses	3	100.0	3	100.0	6	100.0	C31
Larynx	33	97.0	2	100.0	35	97.1	C32
Bronchus and Lung	224	100.0	205	99.5	429	99.8	C34
Thymus	5	100.0	8	100.0	13	100.0	C37
Heart, Mediastinum and Pleura	5	100.0	4	100.0	9	100.0	C38
Bones, Joints and Articular Cartilage of Limbs	4	100.0	2	100.0	6	100.0	C40
Bones, Joints and Articular Cartilage of Other and Unspecified Sites	7	100.0	5	100.0	12	100.0	C41

Site	Male		Female		Total		Site
	N	%MV	N	%MV	N	%MV	
Hematopoietic and Reticuloendothelial Systems	152	100.0	128	100.0	280	100.0	C42
Skin	92	100.0	131	100.0	223	100.0	C44
Peripheral Nerves and Autonomic Nervous System	0	0.0	1	100.0	1	100.0	C47
Retroperitoneum and Peritoneum	5	100.0	7	100.0	12	100.0	C48
Connective, Subcutaneous and Other Soft Tissues	23	100.0	30	100.0	53	100.0	C49
Breast	2	100.0	884	99.8	886	99.8	C50
Vulva	0	0.0	6	100.0	6	100.0	C51
Vagina	0	0.0	3	100.0	3	100.0	C52
Cervix Uteri	0	0.0	109	100.0	109	100.0	C53
Corpus Uteri	0	0.0	125	100.0	125	100.0	C54
Uterus	0	0.0	5	100.0	5	100.0	C55
Ovary	0	0.0	86	100.0	86	100.0	C56
Other and Unspecified Female Genital Organs	0	0.0	3	100.0	3	100.0	C57
Placenta	0	0.0	2	100.0	2	100.0	C58
Penis	6	100.0	0	0.0	6	100.0	C60
Prostate gland	373	99.5	0	0.0	373	99.5	C61
Testis	5	100.0	0	0.0	5	100.0	C62
Other and Unspecified Male Genital Organs	1	100.0	0	0.0	1	100.0	C63
Kidney	73	100.0	30	100.0	103	100.0	C64
Renal Pelvis	5	100.0	8	100.0	13	100.0	C65
Ureter	6	100.0	5	80.0	11	90.9	C66
Bladder	91	98.9	35	100.0	126	99.2	C67
Other and Unspecified Urinary Organs	2	100.0	0	0.0	2	100.0	C68
Eye and Adnexa	18	100.0	18	94.4	36	97.2	C69
Brain	24	95.8	28	100.0	52	98.1	C71
Spinal Cord, Cranial Nerves, And Other Parts of Central Nervous System	0	0.0	4	100.0	4	100.0	C72
Thyroid gland	45	100.0	228	100.0	273	100.0	C73
Adrenal gland	8	87.5	7	100.0	15	93.3	C74
Other Endocrine Glands and Related Structures	2	100.0	1	100.0	3	100.0	C75
Other and Ill-Defined Sites	1	100.0	1	100.0	2	100.0	C76
Lymph Nodes	109	100.0	106	100.0	215	100.0	C77
Unknown Primary Site	12	100.0	8	100.0	20	100.0	C80
<b>All Sites</b>	<b>2,094</b>	<b>96.3</b>	<b>2,755</b>	<b>98.8</b>	<b>4,849</b>	<b>97.7</b>	

**Table 4.3** Number of cancer cases by site, sex and age.

Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.
<b>GRAND TOTAL</b>																					
F	2,755	23	10	15	12	11	39	84	130	176	195	296	294	359	377	303	193	135	103	58.9	16.3
M	2,094	28	11	9	9	16	14	32	44	55	85	144	202	313	352	316	234	142	88	63.2	16.1
T	4,849	51	21	24	21	27	53	116	174	231	280	440	496	672	729	619	427	277	191	60.8	16.3
<b>C00 LIP</b>																					
F	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	69.7	2.5
M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	52.0	*
T	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	65.3	9.1
<b>C01 BASE OF TONGUE</b>																					
F	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	73.5	0.7
M	5	0	0	0	0	0	0	0	0	1	0	0	0	0	3	0	0	1	0	64.8	14.4
T	7	0	0	0	0	0	0	0	0	1	0	0	0	0	3	2	0	1	0	67.3	12.5
<b>C02 OTHER AND UNSPECIFIED PART OF TONGUE</b>																					
F	11	0	0	0	0	0	0	2	0	0	0	3	2	1	1	1	0	0	1	56.4	16.0
M	22	0	0	0	0	0	0	1	1	2	1	5	1	3	2	3	1	2	0	58.8	13.5
T	33	0	0	0	0	0	0	3	1	2	1	8	3	4	3	4	1	2	1	58.0	14.2
<b>C03 GUM</b>																					
F	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	75.3	9.6
M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	63.0	18.4
T	5	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	1	0	70.4	13.3
<b>C04 FLOOR OF MOUTH</b>																					
F	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	69.5	3.5
M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	61.0	*
T	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	66.7	5.5
<b>C05 PALATE</b>																					
F	3	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	0	51.7	27.8
M	5	0	0	0	0	0	0	0	0	1	1	0	2	0	0	0	1	0	0	55.4	13.8
T	8	0	0	0	0	0	0	1	0	2	1	0	2	0	0	0	1	1	0	54.0	18.3
<b>C06 OTHER AND UNSPECIFIED PART OF MOUTH</b>																					
F	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	78.0	*
M	5	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1	0	0	0	61.4	9.8
T	6	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1	1	0	0	64.2	11.1
<b>C07 PAROTID GLAND</b>																					
F	5	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	0	1	61.8	21.6
M	3	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	56.0	13.1
T	8	0	0	0	0	0	0	1	0	1	0	1	0	1	2	1	0	0	1	59.6	18.0
<b>C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS</b>																					
F	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	47.5	33.2
T	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	47.5	33.2
<b>C09 TONSIL</b>																					
F	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	64.5	3.5
M	17	0	0	0	0	0	0	0	1	2	1	1	1	4	2	1	3	1	0	60.9	13.4
T	19	0	0	0	0	0	0	0	1	2	1	1	1	5	3	1	3	1	0	61.3	12.7
<b>C10 OROPHARYNX</b>																					
M	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	51.0	5.7

Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.	
T	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	51.0	5.7	
<b>C11 NASOPHARYNX</b>																						
F	14	0	0	0	0	0	0	0	1	1	0	5	3	3	0	0	0	1	0	55.2	10.5	
M	46	0	0	0	0	1	0	1	1	3	11	7	5	7	2	6	2	0	0	55.0	11.7	
T	60	0	0	0	0	1	0	1	2	4	11	12	8	10	2	6	2	1	0	55.0	11.3	
<b>C12 PYRIFORM SINUS</b>																						
M	7	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	1	0	65.6	11.3
T	7	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	1	1	0	65.6	11.3
<b>C13 HYPOPHARYNX</b>																						
F	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	62.0	*	
M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	45.0	*	
T	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	53.5	12.0	
<b>C15 ESOPHAGUS</b>																						
F	5	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	0	0	0	61.6	5.5	
M	31	0	0	0	0	0	0	0	0	0	2	1	2	9	8	5	1	2	1	65.9	9.0	
T	36	0	0	0	0	0	0	0	0	0	2	2	2	11	10	5	1	2	1	65.3	8.7	
<b>C16 STOMACH</b>																						
F	47	0	0	0	0	0	0	0	2	1	1	4	2	7	11	8	5	5	1	66.4	12.0	
M	36	0	0	0	0	0	0	0	1	0	1	2	7	3	7	3	4	3	5	68.4	12.9	
T	83	0	0	0	0	0	0	0	3	1	2	6	9	10	18	11	9	8	6	67.3	12.3	
<b>C17 SMALL INTESTINE</b>																						
F	9	0	0	0	0	0	0	0	1	0	1	0	2	1	1	0	3	0	0	62.0	14.9	
M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	69.0	7.1	
T	11	0	0	0	0	0	0	0	1	0	1	0	2	2	1	1	3	0	0	63.3	13.8	
<b>C18 COLON</b>																						
F	170	0	0	0	0	0	1	2	1	7	4	15	17	22	23	28	24	14	12	66.8	12.9	
M	197	0	0	0	0	0	0	1	4	6	5	14	22	37	35	30	19	16	8	65.6	11.6	
T	367	0	0	0	0	0	1	3	5	13	9	29	39	59	58	58	43	30	20	66.1	12.2	
<b>C19 RECTOSIGMOID JUNCTION</b>																						
F	14	0	0	0	0	0	0	1	0	0	0	2	2	3	1	2	0	1	2	64.9	15.4	
M	19	0	0	0	0	0	0	1	0	1	1	0	4	4	2	1	2	3	0	63.3	13.2	
T	33	0	0	0	0	0	0	2	0	1	1	2	6	7	3	3	2	4	2	64.0	14.0	
<b>C20 RECTUM</b>																						
F	77	0	0	0	0	0	0	1	8	7	2	7	7	10	10	15	6	4	0	60.3	13.8	
M	98	0	0	1	0	0	0	2	4	0	3	8	7	15	27	12	9	9	1	64.2	13.0	
T	175	0	0	1	0	0	0	3	12	7	5	15	14	25	37	27	15	13	1	62.5	13.4	
<b>C21 ANUS AND ANAL CANAL</b>																						
F	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	65.3	9.6	
M	2	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	45.5	16.3	
T	5	0	0	0	0	0	0	1	0	0	0	0	2	0	1	1	0	0	0	57.4	15.2	
<b>C22 LIVER AND INTRAHEPATIC BILE DUCTS</b>																						
F	102	1	0	1	1	0	0	0	1	1	5	4	9	19	11	21	12	8	8	66.5	15.0	
M	205	1	0	0	0	0	0	1	2	5	10	18	36	41	31	22	21	8	9	63.6	11.9	
T	307	2	0	1	1	0	0	1	3	6	15	22	45	60	42	43	33	16	17	64.5	13.1	
<b>C23 GALLBLADDER</b>																						
F	6	0	0	0	0	0	0	0	0	0	1	0	0	1	3	0	0	0	1	67.3	14.7	

Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.
M	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	1	69.7	23.1
T	9	0	0	0	0	0	0	0	0	0	2	0	0	1	4	0	0	0	2	68.1	16.4
<b>C24 OTHER AND UNSPECIFIED PART OF BILIARY TRACT</b>																					
F	9	0	0	0	0	0	0	0	0	0	0	1	0	1	3	1	1	1	1	71.1	12.4
M	9	0	0	0	0	0	0	0	0	0	2	0	1	1	2	1	1	0	1	64.9	12.9
T	18	0	0	0	0	0	0	0	0	0	2	1	1	2	5	2	2	1	2	68.0	12.7
<b>C25 PANCREAS</b>																					
F	31	0	0	0	0	0	1	0	1	0	0	3	0	4	5	6	5	3	3	69.4	14.6
M	31	0	0	0	0	0	0	1	1	1	1	3	1	12	4	1	4	1	1	62.2	12.4
T	62	0	0	0	0	0	1	1	2	1	1	6	1	16	9	7	9	4	4	65.8	13.9
<b>C30 NASAL CAVITY AND MIDDLE EAR</b>																					
F	5	0	0	0	0	0	0	0	1	0	1	0	1	1	0	1	0	0	0	54.8	13.3
M	8	0	0	0	0	1	0	1	2	0	1	0	0	1	1	0	1	0	0	48.0	18.9
T	13	0	0	0	0	1	0	1	3	0	2	0	1	2	1	1	1	0	0	50.6	16.7
<b>C31 ACCESSORY SINUSES</b>																					
F	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	64.7	12.0
M	3	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	55.0	15.7
T	6	0	0	0	0	0	0	0	0	1	0	2	0	1	0	1	1	0	0	59.8	13.6
<b>C32 LARYNX</b>																					
F	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	75.0	11.3
M	33	0	0	0	0	0	0	0	0	0	1	2	6	5	8	5	4	1	1	66.1	8.7
T	35	0	0	0	0	0	0	0	0	0	1	2	6	5	9	5	4	2	1	66.6	8.9
<b>C34 BRONCHUS AND LUNG</b>																					
F	205	0	0	0	1	0	1	1	1	3	2	19	19	25	46	36	20	20	11	67.1	11.6
M	224	0	0	0	0	0	0	0	3	2	5	18	19	39	41	45	30	11	11	67.1	10.3
T	429	0	0	0	1	0	1	1	4	5	7	37	38	64	87	81	50	31	22	67.1	10.9
<b>C37 THYMUS</b>																					
F	8	0	0	0	0	0	1	0	0	0	2	0	0	0	2	2	0	1	0	59.9	17.3
M	5	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	2	0	67.0	14.4
T	13	0	0	0	0	0	1	0	0	0	2	1	1	1	2	2	0	3	0	62.6	16.0
<b>C38 HEART, MEDIASTINUM AND PLEURA</b>																					
F	4	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	0	0	0	54.5	10.4
M	5	0	0	0	0	1	2	0	0	0	0	0	1	0	0	0	1	0	0	42.2	23.4
T	9	0	0	0	0	1	2	0	0	1	1	0	1	1	1	0	1	0	0	47.7	18.9
<b>C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS</b>																					
F	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	55.5	24.7
M	4	0	0	0	0	1	0	1	0	0	1	0	0	0	0	1	0	0	0	43.0	22.6
T	6	0	0	0	0	1	0	1	1	0	1	0	0	0	0	2	0	0	0	47.2	21.7
<b>C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES</b>																					
F	5	1	0	1	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	27.0	22.2
M	7	1	0	0	0	1	0	0	0	0	0	0	1	1	2	1	0	0	0	50.3	26.6
T	12	2	0	1	1	1	0	0	0	0	1	1	1	1	2	1	0	0	0	40.6	26.6
<b>C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS</b>																					
F	128	8	5	5	0	0	4	2	3	3	5	10	10	16	10	14	12	10	11	56.7	25.5
M	152	8	3	2	4	2	6	1	4	6	11	12	7	10	21	25	13	9	8	56.4	23.3
T	280	16	8	7	4	2	10	3	7	9	16	22	17	26	31	39	25	19	19	56.5	24.3



Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.
<b>C44 SKIN</b>																					
F	131	0	1	2	1	0	2	3	4	4	3	6	5	16	17	17	18	16	16	66.9	18.0
M	92	0	1	0	0	1	0	3	3	0	2	5	12	11	8	12	19	11	4	66.2	15.5
T	223	0	2	2	1	1	2	6	7	4	5	11	17	27	25	29	37	27	20	66.6	16.9
<b>C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM</b>																					
F	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	53.0	*
T	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	53.0	*
<b>C48 RETROPERITONEUM AND PERITONEUM</b>																					
F	7	0	0	0	0	0	0	0	0	1	0	1	1	2	2	0	0	0	0	58.7	8.6
M	5	1	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	1	0	43.4	34.2
T	12	1	0	0	0	1	0	0	1	1	0	1	1	2	2	1	0	1	0	52.3	23.0
<b>C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES</b>																					
F	30	1	0	0	0	0	1	1	2	4	1	6	1	3	3	4	1	0	2	54.9	18.1
M	23	0	0	2	1	2	1	0	4	1	1	0	1	2	1	2	2	2	1	49.4	24.9
T	53	1	0	2	1	2	2	1	6	5	2	6	2	5	4	6	3	2	3	52.5	21.3
<b>C50 BREAST</b>																					
F	884	0	0	0	0	2	6	20	50	79	108	131	119	113	119	68	41	22	6	56.6	12.5
M	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	55.0	29.7
T	886	0	0	0	0	2	6	21	50	79	108	131	119	113	119	68	42	22	6	56.5	12.5
<b>C51 VULVA</b>																					
F	6	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	2	0	64.7	14.3
T	6	0	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	2	0	64.7	14.3
<b>C52 VAGINA</b>																					
F	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	59.7	18.6
T	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	59.7	18.6
<b>C53 CERVIX UTERI</b>																					
F	109	0	0	0	0	0	0	6	16	11	8	13	19	15	6	6	5	1	3	53.7	13.5
T	109	0	0	0	0	0	0	6	16	11	8	13	19	15	6	6	5	1	3	53.7	13.5
<b>C54 CORPUS UTERI</b>																					
F	125	0	0	0	0	0	0	2	1	7	12	12	23	16	25	11	13	3	0	60.5	10.9
T	125	0	0	0	0	0	0	2	1	7	12	12	23	16	25	11	13	3	0	60.5	10.9
<b>C55 UTERUS</b>																					
F	5	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	1	1	66.8	17.0
T	5	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	1	1	66.8	17.0
<b>C56 OVARY</b>																					
F	86	0	0	1	3	1	3	5	5	11	9	8	10	8	8	7	4	2	1	51.9	16.1
T	86	0	0	1	3	1	3	5	5	11	9	8	10	8	8	7	4	2	1	51.9	16.1
<b>C57 OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS</b>																					
F	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	64.0	22.5
T	3	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	64.0	22.5
<b>C58 PLACENTA</b>																					
F	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	48.5	3.5
T	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	48.5	3.5
<b>C60 PENIS</b>																					
M	6	0	0	0	0	0	0	0	1	0	2	1	0	1	0	0	1	0	0	54.0	13.4
T	6	0	0	0	0	0	0	0	1	0	2	1	0	1	0	0	1	0	0	54.0	13.4

Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.	
<b>C61 PROSTATE GLAND</b>																						
M	373	0	0	0	0	0	0	0	0	0	1	6	19	49	89	91	63	38	17	71.1	7.9	
T	373	0	0	0	0	0	0	0	0	0	1	6	19	49	89	91	63	38	17	71.1	7.9	
<b>C62 TESTIS</b>																						
M	5	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	41.6	8.1	
T	5	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	41.6	8.1	
<b>C63 OTHER AND UNSPECIFIED MALE GENITAL ORGANS</b>																						
M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	84.0	*
T	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	84.0	*
<b>C64 KIDNEY</b>																						
F	30	0	0	0	0	0	1	0	0	4	2	1	2	5	7	8	0	0	0	60.2	12.1	
M	73	1	0	0	0	0	0	1	2	9	3	11	6	10	14	9	4	3	0	58.8	13.9	
T	103	1	0	0	0	0	1	1	2	13	5	12	8	15	21	17	4	3	0	59.2	13.3	
<b>C65 RENAL PELVIS</b>																						
F	8	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	2	0	68.1	11.3	
M	5	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	0	0	63.6	6.5	
T	13	0	0	0	0	0	0	0	0	0	0	1	3	2	2	2	1	2	0	66.4	9.7	
<b>C66 URETER</b>																						
F	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	1	76.6	6.9	
M	6	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1	0	2	72.2	15.0	
T	11	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	3	0	3	74.2	11.7	
<b>C67 BLADDER</b>																						
F	35	0	0	0	0	0	1	0	1	0	0	1	3	6	8	5	2	3	5	68.5	13.5	
M	91	0	0	0	0	0	0	0	0	3	3	3	9	16	12	11	14	7	13	69.5	12.3	
T	126	0	0	0	0	0	1	0	1	3	3	4	12	22	20	16	16	10	18	69.2	12.6	
<b>C68 OTHER AND UNSPECIFIED URINARY ORGANS</b>																						
M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	75.0	7.1	
T	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	75.0	7.1	
<b>C69 EYE AND ADNEXA</b>																						
F	18	5	0	1	0	0	0	1	0	1	2	2	4	1	0	1	0	0	0	36.8	25.9	
M	18	7	0	0	0	2	0	0	1	2	1	1	1	0	0	1	1	1	0	31.8	28.8	
T	36	12	0	1	0	2	0	1	1	3	3	3	5	1	0	2	1	1	0	34.3	27.1	
<b>C71 BRAIN</b>																						
F	28	3	0	2	2	1	2	4	1	2	1	4	0	2	1	3	0	0	0	37.8	21.8	
M	24	3	2	0	1	0	0	3	1	0	0	4	4	4	2	0	0	0	0	40.8	23.2	
T	52	6	2	2	3	1	2	7	2	2	1	8	4	6	3	3	0	0	0	39.2	22.3	
<b>C72 SPINAL CORD, CRANIAL NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM</b>																						
F	4	2	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	20.0	30.1	
T	4	2	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	20.0	30.1	
<b>C73 THYROID GLAND</b>																						
F	228	0	0	0	3	4	10	24	23	23	17	24	19	32	21	14	6	5	3	51.2	15.8	
M	45	0	1	0	1	0	3	9	2	2	4	4	3	4	4	4	3	1	0	49.6	18.5	
T	273	0	1	0	4	4	13	33	25	25	21	28	22	36	25	18	9	6	3	50.9	16.3	
<b>C74 ADRENAL GLAND</b>																						
F	7	2	2	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	0	27.9	30.5	
M	8	4	2	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	14.9	21.1	

Site	Total	0+	5+	10+	15+	20+	25+	30+	35+	40+	45+	50+	55+	60+	65+	70+	75+	80+	85+	Mean	S.D.
T	15	6	4	0	0	0	0	0	1	0	1	0	1	1	0	1	0	0	0	20.9	25.8
<b>C75 OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES</b>																					
F	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	34.0	*
M	2	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	19.0	5.7
T	3	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	0	0	24.0	9.5
<b>C76 OTHER AND ILL-DEFINED SITES</b>																					
F	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	64.0	*
M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	55.0	*
T	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	59.5	6.4
<b>C77 LYMPH NODES</b>																					
F	106	0	1	2	0	1	5	6	6	1	2	6	10	12	18	11	8	6	11	60.6	19.4
M	109	2	2	4	1	2	2	2	3	4	3	10	13	13	18	17	5	4	4	57.3	20.1
T	215	2	3	6	1	3	7	8	9	5	5	16	23	25	36	28	13	10	15	58.9	19.8
<b>C80 UNKNOWN PRIMARY SITE</b>																					
F	8	0	0	0	0	1	0	0	0	0	1	0	0	2	1	1	0	1	1	63.6	22.0
M	12	0	0	0	0	0	0	0	0	1	1	3	1	2	1	0	1	2	0	61.4	13.0
T	20	0	0	0	0	1	0	0	0	1	2	3	1	4	2	1	1	3	1	62.3	16.6

**Table 4.4** Number of cancer cases by primary site.

ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
<b>C00 LIP</b>	<b>1</b>	<b>3</b>	<b>4</b>
C00.0 - External upper lip	0	1	1
C00.1 - External lower lip	1	2	3
<b>C01 BASE OF TONGUE</b>	<b>5</b>	<b>2</b>	<b>7</b>
C01.9 - Base of tongue	5	2	7
<b>C02 OTHER AND UNSPECIFIED PART OF TONGUE</b>	<b>22</b>	<b>11</b>	<b>33</b>
C02.1 - Border of tongue	1	0	1
C02.2 - Ventral surface of tongue	1	0	1
C02.9 - Tongue	20	11	31
<b>C03 GUM</b>	<b>2</b>	<b>3</b>	<b>5</b>
C03.1 - Lower gum	1	1	2
C03.9 - Gum	1	2	3
<b>C04 FLOOR OF MOUTH</b>	<b>1</b>	<b>2</b>	<b>3</b>
C04.9 - Floor of mouth	1	2	3
<b>C05 PALATE</b>	<b>5</b>	<b>3</b>	<b>8</b>
C05.0 - Hard palate	0	2	2
C05.1 - Soft palate	4	0	4
C05.2 - Uvula	1	0	1
C05.9 - Palate	0	1	1
<b>C06 OTHER AND UNSPECIFIED PART OF MOUTH</b>	<b>5</b>	<b>1</b>	<b>6</b>
C06.0 - Cheek mucosa	1	0	1
C06.2 - Retromolar area	1	0	1
C06.9 - Mouth	3	1	4
<b>C07 PAROTID GLAND</b>	<b>3</b>	<b>5</b>	<b>8</b>
C07.9 - Parotid gland	3	5	8
<b>C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS</b>	<b>0</b>	<b>2</b>	<b>2</b>
C08.0 - Submandibular gland	0	1	1
C08.9 - Major salivary gland	0	1	1
<b>C09 TONSIL</b>	<b>17</b>	<b>2</b>	<b>19</b>
C09.9 - Tonsil	17	2	19
<b>C10 OROPHARYNX</b>	<b>2</b>	<b>0</b>	<b>2</b>
C10.9 - Oropharynx	2	0	2
<b>C11 NASOPHARYNX</b>	<b>46</b>	<b>14</b>	<b>60</b>
C11.9 - Nasopharynx	46	14	60
<b>C12 PYRIFORM SINUS</b>	<b>7</b>	<b>0</b>	<b>7</b>
C12.9 - Pyriform sinus	7	0	7
<b>C13 HYPOPHARYNX</b>	<b>1</b>	<b>1</b>	<b>2</b>
C13.9 - Hypopharynx	1	1	2
<b>C15 ESOPHAGUS</b>	<b>31</b>	<b>5</b>	<b>36</b>
C15.0 - Cervical esophagus	1	2	3
C15.1 - Thoracic esophagus	4	0	4

ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
C15.3 - Upper third of esophagus	2	0	2
C15.4 - Middle third of esophagus	4	0	4
C15.5 - Lower third of esophagus	8	0	8
C15.9 - Esophagus	12	3	15
<b>C16 STOMACH</b>	<b>36</b>	<b>47</b>	<b>83</b>
C16.0 - Cardia	2	3	5
C16.2 - Body of stomach	3	4	7
C16.3 - Gastric antrum	4	3	7
C16.9 - Stomach	27	37	64
<b>C17 SMALL INTESTINE</b>	<b>2</b>	<b>9</b>	<b>11</b>
C17.0 - Duodenum	1	3	4
C17.1 - Jejunum	0	3	3
C17.2 - Ileum	0	2	2
C17.9 - Small intestine	1	1	2
<b>C18 COLON</b>	<b>197</b>	<b>170</b>	<b>367</b>
C18.0 - Cecum	9	11	20
C18.1 - Appendix	3	2	5
C18.2 - Ascending colon	18	20	38
C18.3 - Hepatic flexure of colon	6	13	19
C18.4 - Transverse colon	13	19	32
C18.5 - Splenic flexure of colon	11	4	15
C18.6 - Descending colon	22	18	40
C18.7 - Sigmoid colon	98	77	175
C18.9 - Colon	17	6	23
<b>C19 RECTOSIGMOID JUNCTION</b>	<b>19</b>	<b>14</b>	<b>33</b>
C19.9 - Rectosigmoid junction	19	14	33
<b>C20 RECTUM</b>	<b>98</b>	<b>77</b>	<b>175</b>
C20.9 - Rectum	98	77	175
<b>C21 ANUS AND ANAL CANAL</b>	<b>2</b>	<b>3</b>	<b>5</b>
C21.1 - Anal canal	2	3	5
<b>C22 LIVER AND INTRAHEPATIC BILE DUCTS</b>	<b>205</b>	<b>102</b>	<b>307</b>
C22.0 - Liver	164	71	235
C22.1 - Intrahepatic bile duct	41	31	72
<b>C23 GALLBLADDER</b>	<b>3</b>	<b>6</b>	<b>9</b>
C23.9 - Gallbladder	3	6	9
<b>C24 OTHER AND UNSPECIFIED PART OF BILIARY TRACT</b>	<b>9</b>	<b>9</b>	<b>18</b>
C24.0 - Extrahepatic bile duct	5	3	8
C24.1 - Ampulla of Vater	4	6	10
<b>C25 PANCREAS</b>	<b>31</b>	<b>31</b>	<b>62</b>
C25.0 - Head of pancreas	18	19	37
C25.1 - Body of pancreas	2	3	5
C25.2 - Tail of pancreas	10	2	12

ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
C25.3 - Pancreatic duct	0	2	2
C25.9 - Pancreas	1	5	6
<b>C30 NASAL CAVITY AND MIDDLE EAR</b>	<b>8</b>	<b>5</b>	<b>13</b>
C30.0 - Nasal cavity	8	5	13
<b>C31 ACCESSORY SINUSES</b>	<b>3</b>	<b>3</b>	<b>6</b>
C31.0 - Maxillary sinus	3	2	5
C31.3 - Sphenoid sinus	0	1	1
<b>C32 LARYNX</b>	<b>33</b>	<b>2</b>	<b>35</b>
C32.0 - Glottis	22	1	23
C32.1 - Supraglottis	8	1	9
C32.3 - Laryngeal cartilage	1	0	1
C32.9 - Larynx	2	0	2
<b>C34 BRONCHUS AND LUNG</b>	<b>224</b>	<b>205</b>	<b>429</b>
C34.1 - Upper lobe, lung	120	94	214
C34.2 - Middle lobe, lung	17	15	32
C34.3 - Lower lobe, lung	70	80	150
C34.8 - Overl. lesion of lung	2	2	4
C34.9 - Lung	15	14	29
<b>C37 THYMUS</b>	<b>5</b>	<b>8</b>	<b>13</b>
C37.9 - Thymus	5	8	13
<b>C38 HEART, MEDIASTINUM AND PLEURA</b>	<b>5</b>	<b>4</b>	<b>9</b>
C38.1 - Anterior mediastinum	0	2	2
C38.3 - Mediastinum	3	0	3
C38.4 - Pleura	2	2	4
<b>C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS</b>	<b>4</b>	<b>3</b>	<b>7</b>
C40.0 - Long bones of upper limb, scapula and associated joints	0	1	1
C40.2 - Long bones of lower limb and associated joints	4	0	4
C40.3 - Short bones of lower limb and associated joints	0	1	1
<b>C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES</b>	<b>7</b>	<b>5</b>	<b>12</b>
C41.0 - Bones of skull and face and associated joints	0	1	1
C41.1 - Mandible	0	1	1
C41.2 - Vertebral column	1	1	2
C41.4 - Pelvic bones, sacrum, coccyx and associated joints	3	2	5
C41.9 - Bone	3	0	3
<b>C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS</b>	<b>152</b>	<b>128</b>	<b>280</b>
C42.1 - Bone marrow	151	128	279
C42.2 - Spleen	1	0	1
<b>C44 SKIN</b>	<b>92</b>	<b>131</b>	<b>223</b>
C44.0 - Skin of lip	0	7	7
C44.1 - Eyelid	5	8	13
C44.2 - External ear	8	5	13

ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
C44.3 - Skin of other and unspecified parts of face	37	57	94
C44.4 - Skin of scalp and neck	5	7	12
C44.5 - Skin of trunk	10	17	27
C44.6 - Skin of upper limb and shoulder	12	12	24
C44.7 - Skin of lower limb and hip	14	13	27
C44.8 - Overl. lesion of skin	1	2	3
C44.9 - Skin	0	3	3
<b>C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM</b>	<b>0</b>	<b>1</b>	<b>1</b>
C47.1 - Peripheral nerves and autonomic nervous system of head, face, and neck	0	1	1
<b>C48 RETROPERITONEUM AND PERITONEUM</b>	<b>5</b>	<b>7</b>	<b>12</b>
C48.0 - Retroperitoneum	4	2	6
C48.1 - Specified parts of peritoneum	1	0	1
C48.2 - Peritoneum	0	5	5
<b>C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES</b>	<b>23</b>	<b>30</b>	<b>53</b>
C49.0 - Connec., subcut. and other soft tissues of head, face, and neck	5	3	8
C49.1 - Connec., subcut. and other soft tissues of upper limb and shoulder	2	4	6
C49.2 - Connec., subcut. and other soft tissues of lower limb and hip	9	7	16
C49.3 - Connec., subcut. and other soft tissues of thorax	1	4	5
C49.4 - Connec., subcut. and other soft tissues of abdomen	1	3	4
C49.5 - Connec., subcut. and other soft tissues of pelvis	2	6	8
C49.6 - Connec., subcut. and other soft tissues of trunk	1	1	2
C49.8 - Overl. lesion of connec., subcut. and other soft tissues	1	0	1
C49.9 - Connec., subcut. and other soft tissues	1	2	3
<b>C50 BREAST</b>	<b>2</b>	<b>884</b>	<b>886</b>
C50.0 - Nipple	0	8	8
C50.1 - Central portion of breast	0	33	33
C50.2 - Upper-inner quadrant of breast	1	119	120
C50.3 - Lower-inner quadrant of breast	0	47	47
C50.4 - Upper-outer quadrant of breast	1	399	400
C50.5 - Lower-outer quadrant of breast	0	52	52
C50.6 - Axillary tail of breast	0	5	5
C50.8 - Overl. lesion of breast	0	72	72
C50.9 - Breast	0	149	149
<b>C51 VULVA</b>	<b>0</b>	<b>6</b>	<b>6</b>
C51.9 - Vulva	0	6	6
<b>C52 VAGINA</b>	<b>0</b>	<b>3</b>	<b>3</b>
C52.9 - Vagina	0	3	3
<b>C53 CERVIX UTERI</b>	<b>0</b>	<b>109</b>	<b>109</b>
C53.0 - Endocervix	0	23	23
C53.1 - Exocervix	0	68	68
C53.9 - Cervix	0	18	18

ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
<b>C54 CORPUS UTERI</b>	<b>0</b>	<b>125</b>	<b>125</b>
C54.1 - Endometrium	0	121	121
C54.2 - Myometrium	0	1	1
C54.9 - Corpus uteri	0	3	3
<b>C55 UTERUS</b>	<b>0</b>	<b>5</b>	<b>5</b>
C55.9 - Uterus	0	5	5
<b>C56 OVARY</b>	<b>0</b>	<b>86</b>	<b>86</b>
C56.9 - Ovary	0	86	86
<b>C57 OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS</b>	<b>0</b>	<b>3</b>	<b>3</b>
C57.0 - Fallopian tube	0	3	3
<b>C58 PLACENTA</b>	<b>0</b>	<b>2</b>	<b>2</b>
C58.9 - Placenta	0	2	2
<b>C60 PENIS</b>	<b>6</b>	<b>0</b>	<b>6</b>
C60.0 - Prepuce	1	0	1
C60.9 - Penis	5	0	5
<b>C61 PROSTATE GLAND</b>	<b>373</b>	<b>0</b>	<b>373</b>
C61.9 - Prostate gland	373	0	373
<b>C62 TESTIS</b>	<b>5</b>	<b>0</b>	<b>5</b>
C62.9 - Testis	5	0	5
<b>C63 OTHER AND UNSPECIFIED MALE GENITAL ORGANS</b>	<b>1</b>	<b>0</b>	<b>1</b>
C63.1 - Spermatic cord	1	0	1
<b>C64 KIDNEY</b>	<b>73</b>	<b>30</b>	<b>103</b>
C64.9 - Kidney	73	30	103
<b>C65 RENAL PELVIS</b>	<b>5</b>	<b>8</b>	<b>13</b>
C65.9 - Renal pelvis	5	8	13
<b>C66 URETER</b>	<b>6</b>	<b>5</b>	<b>11</b>
C66.9 - Ureter	6	5	11
<b>C67 BLADDER</b>	<b>91</b>	<b>35</b>	<b>126</b>
C67.1 - Dome of urinary bladder	1	0	1
C67.4 - Posterior wall of urinary bladder	1	1	2
C67.6 - Ureteric orifice	1	0	1
C67.9 - Bladder	88	34	122
<b>C68 OTHER AND UNSPECIFIED URINARY ORGANS</b>	<b>2</b>	<b>0</b>	<b>2</b>
C68.0 - Urethra	2	0	2
<b>C69 EYE AND ADNEXA</b>	<b>18</b>	<b>18</b>	<b>36</b>
C69.0 - Conjunctiva	2	1	3
C69.2 - Retina	7	7	14
C69.3 - Choroid	8	7	15
C69.4 - Ciliary body	0	1	1
C69.6 - Orbit	1	2	3
<b>C71 BRAIN</b>	<b>24</b>	<b>28</b>	<b>52</b>
C71.1 - Frontal lobe	7	10	17



ICD-O SITE AND HISTOPATHOLOGY	Male	Female	Total
C71.2 - Temporal lobe	10	5	15
C71.3 - Parietal lobe	1	1	2
C71.4 - Occipital lobe	0	2	2
C71.5 - Ventricle	1	0	1
C71.6 - Cerebellum	2	4	6
C71.7 - Brain stem	2	2	4
C71.9 - Brain	1	4	5
<b>C72 SPINAL CORD, CRANIAL NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM</b>	<b>0</b>	<b>4</b>	<b>4</b>
C72.0 - Spinal cord	0	2	2
C72.3 - Optic nerve	0	2	2
<b>C73 THYROID GLAND</b>	<b>45</b>	<b>228</b>	<b>273</b>
C73.9 - Thyroid gland	45	228	273
<b>C74 ADRENAL GLAND</b>	<b>8</b>	<b>7</b>	<b>15</b>
C74.0 - Cortex of adrenal gland	1	0	1
C74.9 - Adrenal gland	7	7	14
<b>C75 OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES</b>	<b>2</b>	<b>1</b>	<b>3</b>
C75.0 - Parathyroid gland	0	1	1
C75.1 - Pituitary gland	1	0	1
C75.3 - Pineal gland	1	0	1
<b>C76 OTHER AND ILL-DEFINED SITES</b>	<b>1</b>	<b>1</b>	<b>2</b>
C76.0 - Head, face of neck	1	0	1
C76.3 - Pelvis	0	1	1
<b>C77 LYMPH NODES</b>	<b>109</b>	<b>106</b>	<b>215</b>
C77.0 - Lymph node of head, face and neck	43	39	82
C77.1 - Intrathoracic lymph nodes	7	10	17
C77.2 - Intra-abdominal lymph nodes	29	23	52
C77.3 - Lymph node of axilla or arm	8	9	17
C77.4 - Lymph nodes of inguinal region or leg	3	7	10
C77.5 - Pelvic lymph nodes	1	3	4
C77.8 - Lymph nodes of multiple regions	1	0	1
C77.9 - Lymph node	17	15	32
<b>C80 UNKNOWN PRIMARY SITE</b>	<b>12</b>	<b>8</b>	<b>20</b>
C80.9 - Unknown primary site	12	8	20

**Table 4.5** Number of cancer cases by pathology according to site.

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C00 LIP</b>					
<b>C00.0</b>	<b>External upper lip</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	0	1	1
<b>C00.1</b>	<b>External lower lip</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8070/3	Squamous cell carcinoma	1	2	3
<b>C01 BASE OF TONGUE</b>					
<b>C01.9</b>	<b>Base of tongue</b>		<b>5</b>	<b>2</b>	<b>7</b>
M	8010/3	Carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	1	1	2
M	8071/3	Squamous cell carcinoma, keratinizing	3	1	4
<b>C02 OTHER AND UNSPECIFIED PART OF TONGUE</b>					
<b>C02.1</b>	<b>Border of tongue</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C02.2</b>	<b>Ventral surface of tongue</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8200/3	Adenoid cystic carcinoma	1	0	1
<b>C02.9</b>	<b>Tongue</b>		<b>20</b>	<b>11</b>	<b>31</b>
M	8070/3	Squamous cell carcinoma	15	10	25
M	8071/3	Squamous cell carcinoma, keratinizing	4	1	5
M	8072/3	Squamous cell carcinoma, nonkeratinizing	1	0	1
<b>C03 GUM</b>					
<b>C03.1</b>	<b>Lower gum</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	1	0	1
M	8071/3	Squamous cell carcinoma, keratinizing	0	1	1
<b>C03.9</b>	<b>Gum</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8070/3	Squamous cell carcinoma	0	2	2
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
<b>C04 FLOOR OF MOUTH</b>					
<b>C04.9</b>	<b>Floor of mouth</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8070/3	Squamous cell carcinoma	1	2	3
<b>C05 PALATE</b>					
<b>C05.0</b>	<b>Hard palate</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	8072/3	Squamous cell carcinoma, nonkeratinizing	0	1	1
M	8200/3	Adenoid cystic carcinoma	0	1	1
<b>C05.1</b>	<b>Soft palate</b>		<b>4</b>	<b>0</b>	<b>4</b>
M	8070/3	Squamous cell carcinoma	3	0	3
M	8072/3	Squamous cell carcinoma, nonkeratinizing	1	0	1
<b>C05.2</b>	<b>Uvula</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C05.9</b>	<b>Palate</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8200/3	Adenoid cystic carcinoma	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C06 OTHER AND UNSPECIFIED PART OF MOUTH</b>					
<b>C06.0</b>	<b>Cheek mucosa</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C06.2</b>	<b>Retromolar area</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C06.9</b>	<b>Mouth</b>		<b>3</b>	<b>1</b>	<b>4</b>
M	8070/3	Squamous cell carcinoma	2	1	3
M	8720/3	Malignant melanoma	1	0	1
<b>C07 PAROTID GLAND</b>					
<b>C07.9</b>	<b>Parotid gland</b>		<b>3</b>	<b>5</b>	<b>8</b>
M	8022/3	Pleomorphic carcinoma	0	2	2
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8082/3	Lymphoepithelial carcinoma	1	0	1
M	8200/3	Adenoid cystic carcinoma	0	2	2
M	8430/3	Mucoepidermoid carcinoma	1	0	1
M	8550/3	Acinar cell adenocarcinoma	0	1	1
<b>C08 OTHER AND UNSPECIFIED MAJOR SALIVARY GLANDS</b>					
<b>C08.0</b>	<b>Submandibular gland</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8200/3	Adenoid cystic carcinoma	0	1	1
<b>C08.9</b>	<b>Major salivary gland</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8083/3	Basaloid carcinoma	0	1	1
<b>C09 TONSIL</b>					
<b>C09.9</b>	<b>Tonsil</b>		<b>17</b>	<b>2</b>	<b>19</b>
M	8010/3	Carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	8	2	10
M	8071/3	Squamous cell carcinoma, keratinizing	2	0	2
M	8072/3	Squamous cell carcinoma, nonkeratinizing	5	0	5
M	8140/3	Adenocarcinoma	1	0	1
<b>C10 OROPHARYNX</b>					
<b>C10.9</b>	<b>Oropharynx</b>		<b>2</b>	<b>0</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	1	0	1
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
<b>C11 NASOPHARYNX</b>					
<b>C11.9</b>	<b>Nasopharynx</b>		<b>46</b>	<b>14</b>	<b>60</b>
M	8010/3	Carcinoma	3	0	3
M	8070/3	Squamous cell carcinoma	4	4	8
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8072/3	Squamous cell carcinoma, nonkeratinizing	38	10	48
<b>C12 PYRIFORM SINUS</b>					
<b>C12.9</b>	<b>Pyiform sinus</b>		<b>7</b>	<b>0</b>	<b>7</b>
M	8010/3	Carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	4	0	4

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8072/3	Squamous cell carcinoma, nonkeratinizing	2	0	2
<b>C13 HYPOPHARYNX</b>					
<b>C13.9</b>	<b>Hypopharynx</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	1	1	2
<b>C15 ESOPHAGUS</b>					
<b>C15.0</b>	<b>Cervical esophagus</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8070/3	Squamous cell carcinoma	1	1	2
M	8071/3	Squamous cell carcinoma, keratinizing	0	1	1
<b>C15.1</b>	<b>Thoracic esophagus</b>		<b>4</b>	<b>0</b>	<b>4</b>
M	8010/3	Carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	3	0	3
<b>C15.3</b>	<b>Upper third of esophagus</b>		<b>2</b>	<b>0</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	2	0	2
<b>C15.4</b>	<b>Middle third of esophagus</b>		<b>4</b>	<b>0</b>	<b>4</b>
M	8070/3	Squamous cell carcinoma	4	0	4
<b>C15.5</b>	<b>Lower third of esophagus</b>		<b>8</b>	<b>0</b>	<b>8</b>
M	8070/3	Squamous cell carcinoma	5	0	5
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8140/3	Adenocarcinoma	2	0	2
<b>C15.9</b>	<b>Esophagus</b>		<b>12</b>	<b>3</b>	<b>15</b>
M	8010/3	Carcinoma	1	0	1
M	8041/3	Small cell carcinoma	1	0	1
M	8070/2	Squamous cell carcinoma in situ	1	0	1
M	8070/3	Squamous cell carcinoma	5	1	6
M	8072/3	Squamous cell carcinoma, nonkeratinizing	2	0	2
M	8140/3	Adenocarcinoma	0	1	1
M	8246/3	Neuroendocrine carcinoma	1	0	1
M	8720/3	Malignant melanoma	1	0	1
M	8936/3	GIST, malignant	0	1	1
<b>C16 STOMACH</b>					
<b>C16.0</b>	<b>Cardia</b>		<b>2</b>	<b>3</b>	<b>5</b>
M	8140/3	Adenocarcinoma	2	1	3
M	8490/3	Signet ring cell adenocarcinoma	0	1	1
M	8936/3	GIST, malignant	0	1	1
<b>C16.2</b>	<b>Body of stomach</b>		<b>3</b>	<b>4</b>	<b>7</b>
M	8140/3	Adenocarcinoma	3	2	5
M	8490/3	Signet ring cell adenocarcinoma	0	1	1
M	8936/3	GIST, malignant	0	1	1
<b>C16.3</b>	<b>Gastric antrum</b>		<b>4</b>	<b>3</b>	<b>7</b>
M	8140/3	Adenocarcinoma	3	3	6
M	8490/3	Signet ring cell adenocarcinoma	1	0	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C16.9</b>	<b>Stomach</b>		<b>27</b>	<b>37</b>	<b>64</b>
M	8010/3	Carcinoma	3	1	4
M	8140/3	Adenocarcinoma	16	20	36
M	8490/3	Signet ring cell adenocarcinoma	4	7	11
M	8936/3	GIST, malignant	4	9	13
<b>C17 SMALL INTESTINE</b>					
<b>C17.0</b>	<b>Duodenum</b>		<b>1</b>	<b>3</b>	<b>4</b>
M	8140/3	Adenocarcinoma	0	1	1
M	8936/3	GIST, malignant	1	2	3
<b>C17.1</b>	<b>Jejunum</b>		<b>0</b>	<b>3</b>	<b>3</b>
M	8936/3	GIST, malignant	0	3	3
<b>C17.2</b>	<b>Ileum</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	8140/3	Adenocarcinoma	0	1	1
M	8936/3	GIST, malignant	0	1	1
<b>C17.9</b>	<b>Small intestine</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	8936/3	GIST, malignant	1	1	2
<b>C18 COLON</b>					
<b>C18.0</b>	<b>Cecum</b>		<b>9</b>	<b>11</b>	<b>20</b>
M	8140/3	Adenocarcinoma	9	10	19
M	8480/3	Mucinous adenocarcinoma	0	1	1
<b>C18.1</b>	<b>Appendix</b>		<b>3</b>	<b>2</b>	<b>5</b>
M	8010/3	Carcinoma	1	0	1
M	8140/3	Adenocarcinoma	1	1	2
M	8480/3	Mucinous adenocarcinoma	1	1	2
<b>C18.2</b>	<b>Ascending colon</b>		<b>18</b>	<b>20</b>	<b>38</b>
M	8140/2	Adenocarcinoma in situ	1	0	1
M	8140/3	Adenocarcinoma	17	19	36
M	8480/3	Mucinous adenocarcinoma	0	1	1
<b>C18.3</b>	<b>Hepatic flexure of colon</b>		<b>6</b>	<b>13</b>	<b>19</b>
M	8140/3	Adenocarcinoma	5	13	18
M	8480/3	Mucinous adenocarcinoma	1	0	1
<b>C18.4</b>	<b>Transverse colon</b>		<b>13</b>	<b>19</b>	<b>32</b>
M	8140/3	Adenocarcinoma	11	19	30
M	8480/3	Mucinous adenocarcinoma	2	0	2
<b>C18.5</b>	<b>Splenic flexure of colon</b>		<b>11</b>	<b>4</b>	<b>15</b>
M	8140/3	Adenocarcinoma	10	4	14
M	8480/3	Mucinous adenocarcinoma	1	0	1
<b>C18.6</b>	<b>Descending colon</b>		<b>22</b>	<b>18</b>	<b>40</b>
M	8140/3	Adenocarcinoma	22	17	39
M	8500/3	Infiltrating duct carcinoma	0	1	1
<b>C18.7</b>	<b>Sigmoid colon</b>		<b>98</b>	<b>77</b>	<b>175</b>
M	8140/3	Adenocarcinoma	95	76	171

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8480/3	Mucinous adenocarcinoma	2	1	3
M	8510/3	Medullary carcinoma	1	0	1
<b>C18.9</b>	<b>Colon</b>		<b>17</b>	<b>6</b>	<b>23</b>
M	8140/3	Adenocarcinoma	16	6	22
M	8480/3	Mucinous adenocarcinoma	1	0	1
<b>C19 RECTOSIGMOID JUNCTION</b>					
<b>C19.9</b>	<b>Rectosigmoid junction</b>		<b>19</b>	<b>14</b>	<b>33</b>
M	8140/3	Adenocarcinoma	18	14	32
M	8480/3	Mucinous adenocarcinoma	1	0	1
<b>C20 RECTUM</b>					
<b>C20.9</b>	<b>Rectum</b>		<b>98</b>	<b>77</b>	<b>175</b>
M	8010/3	Carcinoma	1	1	2
M	8140/3	Adenocarcinoma	94	72	166
M	8246/3	Neuroendocrine carcinoma	2	2	4
M	8480/3	Mucinous adenocarcinoma	0	1	1
M	8490/3	Signet ring cell adenocarcinoma	1	1	2
<b>C21 ANUS AND ANAL CANAL</b>					
<b>C21.1</b>	<b>Anal canal</b>		<b>2</b>	<b>3</b>	<b>5</b>
M	8070/2	Squamous cell carcinoma in situ	1	0	1
M	8070/3	Squamous cell carcinoma	1	2	3
M	8140/3	Adenocarcinoma	0	1	1
<b>C22 LIVER AND INTRAHEPATIC BILE DUCTS</b>					
<b>C22.0</b>	<b>Liver</b>		<b>164</b>	<b>71</b>	<b>235</b>
M	8010/3	Carcinoma	0	1	1
M	8140/3	Adenocarcinoma	1	1	2
M	8170/3	Hepatocellular carcinoma	159	66	225
M	8180/3	Combined hepatocellular carcinoma and cholangiocarcinoma	2	0	2
M	8970/3	Hepatoblastoma	1	3	4
M	9120/3	Angiosarcoma	1	0	1
<b>C22.1</b>	<b>Intrahepatic bile duct</b>		<b>41</b>	<b>31</b>	<b>72</b>
M	8160/3	Cholangiocarcinoma	41	31	72
<b>C23 GALLBLADDER</b>					
<b>C23.9</b>	<b>Gallbladder</b>		<b>3</b>	<b>6</b>	<b>9</b>
M	8010/3	Carcinoma	2	2	4
M	8140/3	Adenocarcinoma	1	3	4
M	8560/3	Adenosquamous carcinoma	0	1	1
<b>C24 OTHER AND UNSPECIFIED PART OF BILIARY TRACT</b>					
<b>C24.0</b>	<b>Extrahepatic bile duct</b>		<b>5</b>	<b>3</b>	<b>8</b>
M	8140/3	Adenocarcinoma	3	0	3
M	8160/3	Cholangiocarcinoma	2	3	5

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C24.1</b>	<b>Ampulla of Vater</b>		<b>4</b>	<b>6</b>	<b>10</b>
M	8010/3	Carcinoma	0	2	2
M	8140/3	Adenocarcinoma	2	3	5
M	8160/3	Cholangiocarcinoma	2	1	3
<b>C25 PANCREAS</b>					
<b>C25.0</b>	<b>Head of pancreas</b>		<b>18</b>	<b>19</b>	<b>37</b>
M	8010/3	Carcinoma	1	1	2
M	8140/3	Adenocarcinoma	15	17	32
M	8500/3	Infiltrating duct carcinoma	2	0	2
M	9473/3	PNET	0	1	1
<b>C25.1</b>	<b>Body of pancreas</b>		<b>2</b>	<b>3</b>	<b>5</b>
M	8140/3	Adenocarcinoma	1	2	3
M	9473/3	PNET	1	1	2
<b>C25.2</b>	<b>Tail of pancreas</b>		<b>10</b>	<b>2</b>	<b>12</b>
M	8010/3	Carcinoma	1	1	2
M	8140/3	Adenocarcinoma	9	1	10
<b>C25.3</b>	<b>Pancreatic duct</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	8140/3	Adenocarcinoma	0	2	2
<b>C25.9</b>	<b>Pancreas</b>		<b>1</b>	<b>5</b>	<b>6</b>
M	8010/3	Carcinoma	0	1	1
M	8140/3	Adenocarcinoma	1	3	4
M	8246/3	Neuroendocrine carcinoma	0	1	1
<b>C30 NASAL CAVITY AND MIDDLE EAR</b>					
<b>C30.0</b>	<b>Nasal cavity</b>		<b>8</b>	<b>5</b>	<b>13</b>
M	8020/3	Undifferentiated carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	2	1	3
M	8072/3	Squamous cell carcinoma, nonkeratinizing	1	0	1
M	8121/3	Sinonasal undifferentiated carcinoma	0	1	1
M	8140/3	Adenocarcinoma	2	0	2
M	8246/3	Neuroendocrine carcinoma	1	1	2
M	8720/3	Malignant melanoma	0	1	1
M	9522/3	Esthesioneuroblastoma	1	1	2
<b>C31 ACCESSORY SINUSES</b>					
<b>C31.0</b>	<b>Maxillary sinus</b>		<b>3</b>	<b>2</b>	<b>5</b>
M	8032/3	Spindle cell carcinoma	1	0	1
M	8051/3	Verrucous squamous cell carcinoma	1	0	1
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8072/3	Squamous cell carcinoma, nonkeratinizing	0	1	1
M	8200/3	Adenoid cystic carcinoma	0	1	1
<b>C31.3</b>	<b>Sphenoid sinus</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8140/3	Adenocarcinoma	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C32 LARYNX</b>					
<b>C32.0</b>	<b>Glottis</b>		<b>22</b>	<b>1</b>	<b>23</b>
M	8010/2	Carcinoma in situ	2	0	2
M	8070/2	Squamous cell carcinoma in situ	0	1	1
M	8070/3	Squamous cell carcinoma	16	0	16
M	8071/3	Squamous cell carcinoma, keratinizing	2	0	2
M	8076/3	microinvasive squamous cell carcinoma	2	0	2
<b>C32.1</b>	<b>Supraglottis</b>		<b>8</b>	<b>1</b>	<b>9</b>
M	8070/3	Squamous cell carcinoma	7	0	7
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8076/3	microinvasive squamous cell carcinoma	0	1	1
<b>C32.3</b>	<b>Laryngeal cartilage</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C32.9</b>	<b>Larynx</b>		<b>2</b>	<b>0</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	2	0	2
<b>C34 LUNG AND BRONCHUS</b>					
<b>C34.1</b>	<b>Upper lobe, lung</b>		<b>120</b>	<b>94</b>	<b>214</b>
M	8010/3	Carcinoma	3	1	4
M	8013/3	Large cell neuroendocrine carcinoma	1	0	1
M	8032/3	Spindle cell carcinoma	1	0	1
M	8033/3	Sarcomatoid carcinoma	1	0	1
M	8041/3	Small cell carcinoma	9	1	10
M	8046/3	Non-small cell carcinoma	30	24	54
M	8070/3	Squamous cell carcinoma	14	1	15
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8140/3	Adenocarcinoma	56	61	117
M	8240/3	Carcinoid tumour	0	1	1
M	8430/3	Mucoepidermoid carcinoma	0	1	1
M	8550/3	Acinar cell adenocarcinoma	2	4	6
M	8560/3	Adenosquamous carcinoma	2	0	2
<b>C34.2</b>	<b>Middle lobe, lung</b>		<b>17</b>	<b>15</b>	<b>32</b>
M	8004/3	Malignant tumor, spindle cell type	1	0	1
M	8010/3	Carcinoma	0	1	1
M	8046/3	Non-small cell carcinoma	3	1	4
M	8070/3	Squamous cell carcinoma	2	0	2
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8140/3	Adenocarcinoma	8	11	19
M	8246/3	Neuroendocrine carcinoma	1	0	1
M	8256/3	Minimally invasive adenocarcinoma, non-mucinous	1	0	1
M	8480/3	Mucinous adenocarcinoma	0	2	2
<b>C34.3</b>	<b>Lower lobe, lung</b>		<b>70</b>	<b>80</b>	<b>150</b>
M	8010/3	Carcinoma	2	2	4



ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8041/3	Small cell carcinoma	0	1	1
M	8046/3	Non-small cell carcinoma	16	16	32
M	8070/3	Squamous cell carcinoma	11	0	11
M	8140/3	Adenocarcinoma	39	61	100
M	8550/3	Acinar cell adenocarcinoma	1	0	1
M	8560/3	Adenosquamous carcinoma	1	0	1
<b>C34.8</b>	<b>Overl. lesion of lung</b>		<b>2</b>	<b>2</b>	<b>4</b>
M	8041/3	Small cell carcinoma	0	1	1
M	8140/3	Adenocarcinoma	2	1	3
<b>C34.9</b>	<b>Lung</b>		<b>15</b>	<b>14</b>	<b>29</b>
M	8010/3	Carcinoma	4	2	6
M	8041/3	Small cell carcinoma	2	1	3
M	8046/3	Non-small cell carcinoma	4	2	6
M	8070/3	Squamous cell carcinoma	1	0	1
M	8140/3	Adenocarcinoma	3	8	11
M	8550/3	Acinar cell adenocarcinoma	0	1	1
M	8560/3	Adenosquamous carcinoma	1	0	1
<b>C37 THYMUS</b>					
<b>C37.9</b>	<b>Thymus</b>		<b>5</b>	<b>8</b>	<b>13</b>
M	8580/3	Thymoma, malignant	0	1	1
M	8581/3	Thymoma, type A, malignant	0	2	2
M	8582/3	Thymoma, type AB, malignant	1	2	3
M	8584/3	Thymoma, type B2, malignant	0	2	2
M	8585/3	Thymoma, type B3, malignant	1	0	1
M	8586/3	Thymic carcinoma	2	1	3
M	9080/3	Immature teratoma	1	0	1
<b>C38 HEART, MEDIASTINUM AND PLEURA</b>					
<b>C38.1</b>	<b>Anterior mediastinum</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	8582/3	Thymoma, type AB, malignant	0	1	1
M	8584/3	Thymoma, type B2, malignant	0	1	1
<b>C38.3</b>	<b>Mediastinum</b>		<b>3</b>	<b>0</b>	<b>3</b>
M	8020/3	Undifferentiated carcinoma	1	0	1
M	9061/3	Seminoma	1	0	1
M	9064/3	Germ cell tumor	1	0	1
<b>C38.4</b>	<b>Pleura</b>		<b>2</b>	<b>2</b>	<b>4</b>
M	9050/3	Mesothelioma, malignant	2	2	4
<b>C40 BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS</b>					
<b>C40.0</b>	<b>Long bones of upper limb, scapula and associated joints</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	9220/3	Chondrosarcoma	0	1	1
<b>C40.2</b>	<b>Long bones of lower limb and associated joints</b>		<b>4</b>	<b>0</b>	<b>4</b>
M	9180/3	Osteosarcoma	2	0	2
M	9220/3	Chondrosarcoma	1	0	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9260/3	Ewing sarcoma	1	0	1
<b>C40.3</b>	<b>Short bones of lower limb and associated joints</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	9731/3	Solitary plasmacytoma	0	1	1
<b>C41 BONES, JOINTS AND ARTICULAR CARTILAGE OF OTHER AND UNSPECIFIED SITES</b>					
<b>C41.0</b>	<b>Bones of skull and face and associated joints</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	9220/3	Chondrosarcoma	0	1	1
<b>C41.1</b>	<b>Mandible</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	9180/3	Osteosarcoma	0	1	1
<b>C41.2</b>	<b>Vertebral column</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	9180/3	Osteosarcoma	0	1	1
M	9500/3	Neuroblastoma	1	0	1
<b>C41.4</b>	<b>Pelvic bones, sacrum, coccyx and associated joints</b>		<b>3</b>	<b>2</b>	<b>5</b>
M	9180/3	Osteosarcoma	1	0	1
M	9220/3	Chondrosarcoma	1	1	2
M	9370/3	Chordoma	1	1	2
<b>C41.9</b>	<b>Bone</b>		<b>3</b>	<b>0</b>	<b>3</b>
M	8542/3	Extramammary Paget disease	1	0	1
M	9220/3	Chondrosarcoma	1	0	1
M	9260/3	Ewing sarcoma	1	0	1
<b>C42 HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS</b>					
<b>C42.1</b>	<b>Bone marrow</b>		<b>151</b>	<b>128</b>	<b>279</b>
M	9731/3	Solitary plasmacytoma	1	0	1
M	9732/3	Multiple myeloma	31	25	56
M	9733/3	Plasma cell leukemia	1	0	1
M	9761/3	Waldenstrom macroglobulinemia	1	0	1
M	9801/3	Acute leukemia	1	0	1
M	9820/3	Subacute lymphocytic leukemia	0	1	1
M	9823/3	Chronic lymphocytic leukemia	12	5	17
M	9826/3	Acute lymphoblastic leukemia, mature, B-cell type	2	3	5
M	9835/3	Acute lymphoblastic leukemia	3	9	12
M	9836/3	Precursor B-cell lymphoblastic leukemia	5	6	11
M	9837/3	Precursor T-cell lymphoblastic leukemia	2	3	5
M	9860/3	Myelomonocytic leukemia	0	2	2
M	9861/3	Acute myeloid leukemia	16	19	35
M	9863/3	Chronic myeloid leukemia	15	7	22
M	9872/3	Acute myeloblastic leukemia	7	2	9
M	9931/3	Acute myelofibrosis	1	0	1
M	9940/3	Hairy cell leukemia	1	0	1
M	9945/3	Chronic myelomonocytic leukemia	1	0	1
M	9946/3	Juvenile myelomonocytic leukemia	1	1	2
M	9950/3	Polycythemia vera	10	3	13
M	9960/3	Chronic myeloproliferative disease	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9961/3	Chronic idiopathic myelofibrosis	1	0	1
M	9962/3	Essential thrombocythemia	10	13	23
M	9989/3	Myelodysplastic syndrome	29	28	57
<b>C42.2</b>	<b>Spleen</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9120/3	Angiosarcoma	1	0	1
<b>C44 SKIN</b>					
<b>C44.0</b>	<b>Skin of lip</b>		<b>0</b>	<b>7</b>	<b>7</b>
M	8070/2	Squamous cell carcinoma in situ	0	1	1
M	8090/3	Basal cell carcinoma	0	5	5
M	8720/3	Malignant melanoma	0	1	1
<b>C44.1</b>	<b>Eyelid</b>		<b>5</b>	<b>8</b>	<b>13</b>
M	8070/3	Squamous cell carcinoma	1	0	1
M	8090/3	Basal cell carcinoma	4	5	9
M	8097/3	Nodular basal cell carcinoma	0	1	1
M	8410/3	Sebaceous carcinoma	0	2	2
<b>C44.2</b>	<b>External ear</b>		<b>8</b>	<b>5</b>	<b>13</b>
M	8070/2	Squamous cell carcinoma in situ	0	1	1
M	8070/3	Squamous cell carcinoma	3	2	5
M	8071/3	Squamous cell carcinoma, keratinizing	1	0	1
M	8090/3	Basal cell carcinoma	4	2	6
<b>C44.3</b>	<b>Skin of other and unspecified parts of face</b>		<b>37</b>	<b>57</b>	<b>94</b>
M	8070/2	Squamous cell carcinoma in situ	1	0	1
M	8070/3	Squamous cell carcinoma	9	5	14
M	8081/2	Bowen disease	1	0	1
M	8090/3	Basal cell carcinoma	24	40	64
M	8092/3	Infiltrating basal cell carcinoma	0	1	1
M	8097/3	Nodular basal cell carcinoma	0	8	8
M	8720/3	Malignant melanoma	1	3	4
M	8920/3	Alveolar rhabdomyosarcoma	1	0	1
<b>C44.4</b>	<b>Skin of scalp and neck</b>		<b>5</b>	<b>7</b>	<b>12</b>
M	8070/3	Squamous cell carcinoma	2	3	5
M	8090/3	Basal cell carcinoma	2	4	6
M	8720/3	Malignant melanoma	1	0	1
<b>C44.5</b>	<b>Skin of trunk</b>		<b>10</b>	<b>17</b>	<b>27</b>
M	8070/3	Squamous cell carcinoma	4	3	7
M	8081/2	Bowen disease	0	1	1
M	8090/3	Basal cell carcinoma	3	4	7
M	8140/3	Adenocarcinoma	0	1	1
M	8542/3	Extramammary Paget disease	1	0	1
M	8720/3	Malignant melanoma	2	5	7
M	8832/3	Dermatofibrosarcoma protuberans	0	1	1
M	8940/3	Malignant chondroid syringoma	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9700/3	Mycosis fungoides	0	1	1
<b>C44.6</b>	<b>Skin of upper limb and shoulder</b>		<b>12</b>	<b>12</b>	<b>24</b>
M	8070/3	Squamous cell carcinoma	8	5	13
M	8072/3	Squamous cell carcinoma, nonkeratinizing	1	0	1
M	8081/2	Bowen disease	0	1	1
M	8090/3	Basal cell carcinoma	1	2	3
M	8720/2	Melanoma in situ	0	2	2
M	8720/3	Malignant melanoma	2	1	3
M	8832/3	Dermatofibrosarcoma protuberans	0	1	1
<b>C44.7</b>	<b>Skin of lower limb and hip</b>		<b>14</b>	<b>13</b>	<b>27</b>
M	8070/3	Squamous cell carcinoma	6	3	9
M	8090/3	Basal cell carcinoma	1	2	3
M	8409/3	Eccrine poroma, malignant	1	0	1
M	8720/3	Malignant melanoma	3	7	10
M	8721/3	Nodular melanoma	0	1	1
M	8832/3	Dermatofibrosarcoma protuberans	1	0	1
M	9700/3	Mycosis fungoides	2	0	2
<b>C44.8</b>	<b>Overl. lesion of skin</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8081/2	Bowen disease	1	0	1
M	9700/3	Mycosis fungoides	0	2	2
<b>C44.9</b>	<b>Skin</b>		<b>0</b>	<b>3</b>	<b>3</b>
M	8720/3	Malignant melanoma	0	2	2
M	9700/3	Mycosis fungoides	0	1	1
<b>C47 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM</b>					
<b>C47.1</b>	<b>Peripheral nerves and autonomic nervous system of head, face, and neck</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	9540/3	Malignant peripheral nerve sheath tumor	0	1	1
<b>C48 RETROPERITONEUM AND PERITONEUM</b>					
<b>C48.0</b>	<b>Retroperitoneum</b>		<b>4</b>	<b>2</b>	<b>6</b>
M	8800/3	Sarcoma	1	0	1
M	8830/3	Undifferentiated pleomorphic sarcoma	0	1	1
M	8850/3	Liposarcoma	1	1	2
M	8890/3	Leiomyosarcoma	1	0	1
M	9080/3	Immature teratoma	1	0	1
<b>C48.1</b>	<b>Specified parts of peritoneum</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8806/3	Desmoplastic round cell tumor	1	0	1
<b>C48.2</b>	<b>Peritoneum</b>		<b>0</b>	<b>5</b>	<b>5</b>
M	8140/3	Adenocarcinoma	0	3	3
M	8441/3	Serous adenocarcinoma	0	1	1
M	9050/3	Mesothelioma of peritoneum	0	1	1
<b>C49 CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES</b>					
<b>C49.0</b>	<b>Connec., subcut. and other soft tissues of head, face, and neck</b>		<b>5</b>	<b>3</b>	<b>8</b>

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8800/3	Sarcoma	1	0	1
M	8801/3	Spindle cell sarcoma	1	1	2
M	8803/3	Round cell sarcoma	1	0	1
M	8811/3	Myxofibrosarcoma	0	1	1
M	8830/3	Undifferentiated pleomorphic sarcoma	1	0	1
M	8920/3	Alveolar rhabdomyosarcoma	0	1	1
M	9120/3	Angiosarcoma	1	0	1
<b>C49.1</b>	<b>Connec., subcut. and other soft tissues of upper limb and shoulder</b>		<b>2</b>	<b>4</b>	<b>6</b>
M	8800/3	Sarcoma	0	1	1
M	8804/3	Epithelioid sarcoma	0	1	1
M	8811/3	Myxofibrosarcoma	1	1	2
M	9040/3	Synovial sarcoma	1	1	2
<b>C49.2</b>	<b>Connec., subcut. and other soft tissues of lower limb and hip</b>		<b>9</b>	<b>7</b>	<b>16</b>
M	8800/3	Sarcoma	1	0	1
M	8802/3	Pleomorphic cell sarcoma	1	1	2
M	8811/3	Myxofibrosarcoma	0	1	1
M	8830/3	Undifferentiated pleomorphic sarcoma	2	0	2
M	8850/3	Liposarcoma	3	2	5
M	8852/3	Myxoid liposarcoma	1	1	2
M	8854/3	Pleomorphic liposarcoma	0	1	1
M	9040/3	Synovial sarcoma	0	1	1
M	9260/3	Ewing sarcoma	1	0	1
<b>C49.3</b>	<b>Connec., subcut. and other soft tissues of thorax</b>		<b>1</b>	<b>4</b>	<b>5</b>
M	8800/3	Sarcoma	0	1	1
M	8803/3	Round cell sarcoma	1	0	1
M	8811/3	Myxofibrosarcoma	0	1	1
M	8858/3	Dedifferentiated liposarcoma	0	1	1
M	9040/3	Synovial sarcoma	0	1	1
<b>C49.4</b>	<b>Connec., subcut. and other soft tissues of abdomen</b>		<b>1</b>	<b>3</b>	<b>4</b>
M	8800/3	Sarcoma	0	1	1
M	8830/3	Undifferentiated pleomorphic sarcoma	1	1	2
M	8890/3	Leiomyosarcoma	0	1	1
<b>C49.5</b>	<b>Connec., subcut. and other soft tissues of pelvis</b>		<b>2</b>	<b>6</b>	<b>8</b>
M	8800/3	Sarcoma	0	1	1
M	8801/3	Spindle cell sarcoma	0	1	1
M	8804/3	Epithelioid sarcoma	1	0	1
M	8830/3	Undifferentiated pleomorphic sarcoma	1	0	1
M	8850/3	Liposarcoma	0	1	1
M	8890/3	Leiomyosarcoma	0	1	1
M	8900/3	Rhabdomyosarcoma	0	1	1
M	8910/3	Embryonal rhabdomyosarcoma	0	1	1
<b>C49.6</b>	<b>Connec., subcut. and other soft tissues of trunk</b>		<b>1</b>	<b>1</b>	<b>2</b>

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8830/3	Undifferentiated pleomorphic sarcoma	1	0	1
M	8850/3	Liposarcoma	0	1	1
<b>C49.8</b>	<b>Overl. lesion of connec., subcut. and other soft tissues</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9140/3	Kaposi sarcoma	1	0	1
<b>C49.9</b>	<b>Connec., subcut. and other soft tissues</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8800/3	Sarcoma	0	1	1
M	8890/3	Leiomyosarcoma	1	1	2
<b>C50 BREAST</b>					
<b>C50.0</b>	<b>Nipple</b>		<b>0</b>	<b>8</b>	<b>8</b>
M	8500/2	Ductal carcinoma in situ NOS	0	1	1
M	8500/3	Infiltrating duct carcinoma	0	7	7
<b>C50.1</b>	<b>Central portion of breast</b>		<b>0</b>	<b>33</b>	<b>33</b>
M	8010/3	Carcinoma	0	1	1
M	8480/3	Mucinous adenocarcinoma	0	2	2
M	8500/2	Ductal carcinoma in situ NOS	0	4	4
M	8500/3	Infiltrating duct carcinoma	0	26	26
<b>C50.2</b>	<b>Upper-inner quadrant of breast</b>		<b>1</b>	<b>119</b>	<b>120</b>
M	8480/3	Mucinous adenocarcinoma	0	1	1
M	8500/2	Ductal carcinoma in situ NOS	1	9	10
M	8500/3	Infiltrating duct carcinoma	0	106	106
M	8520/3	Invasive lobular carcinoma	0	3	3
<b>C50.3</b>	<b>Lower-inner quadrant of breast</b>		<b>0</b>	<b>47</b>	<b>47</b>
M	8500/2	Ductal carcinoma in situ NOS	0	4	4
M	8500/3	Infiltrating duct carcinoma	0	39	39
M	8503/3	Invasive papillary carcinoma	0	1	1
M	8507/3	Invasive micropapillary carcinoma	0	2	2
M	9020/3	Phyllodes tumor, malignant	0	1	1
<b>C50.4</b>	<b>Upper-outer quadrant of breast</b>		<b>1</b>	<b>399</b>	<b>400</b>
M	8050/3	Papillary carcinoma	0	2	2
M	8211/3	Tubular carcinoma	0	1	1
M	8343/3	Papillary carcinoma, encapsulate	0	4	4
M	8480/3	Mucinous adenocarcinoma	0	5	5
M	8500/2	Ductal carcinoma in situ NOS	0	54	54
M	8500/3	Infiltrating duct carcinoma	1	323	324
M	8503/3	Invasive papillary carcinoma	0	2	2
M	8507/3	Invasive micropapillary carcinoma	0	1	1
M	8509/3	Solid papillary carcinoma	0	2	2
M	8520/2	Lobular carcinoma in situ	0	1	1
M	8520/3	Invasive lobular carcinoma	0	2	2
M	9020/3	Phyllodes tumor, malignant	0	2	2
<b>C50.5</b>	<b>Lower-outer quadrant of breast</b>		<b>0</b>	<b>52</b>	<b>52</b>
M	8480/3	Mucinous adenocarcinoma	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8500/2	Ductal carcinoma in situ NOS	0	6	6
M	8500/3	Infiltrating duct carcinoma	0	41	41
M	8503/3	Invasive papillary carcinoma	0	1	1
M	8507/3	Invasive micropapillary carcinoma	0	2	2
M	9020/3	Phyllodes tumor, malignant	0	1	1
<b>C50.6</b>	<b>Axillary tail of breast</b>		<b>0</b>	<b>5</b>	<b>5</b>
M	8500/3	Infiltrating duct carcinoma	0	5	5
<b>C50.8</b>	<b>Overl. lesion of breast</b>		<b>0</b>	<b>72</b>	<b>72</b>
M	8010/3	Carcinoma	0	1	1
M	8200/3	Adenoid cystic carcinoma	0	1	1
M	8480/3	Mucinous adenocarcinoma	0	1	1
M	8500/2	Ductal carcinoma in situ NOS	0	9	9
M	8500/3	Infiltrating duct carcinoma	0	58	58
M	8520/3	Invasive lobular carcinoma	0	2	2
<b>C50.9</b>	<b>Breast</b>		<b>0</b>	<b>149</b>	<b>149</b>
M	8010/3	Carcinoma	0	8	8
M	8050/2	Papillary carcinoma in situ	0	1	1
M	8050/3	Papillary carcinoma	0	1	1
M	8140/3	Adenocarcinoma	0	1	1
M	8480/3	Mucinous adenocarcinoma	0	2	2
M	8500/2	Ductal carcinoma in situ NOS	0	11	11
M	8500/3	Infiltrating duct carcinoma	0	122	122
M	8520/3	Invasive lobular carcinoma	0	2	2
M	9020/3	Phyllodes tumor, malignant	0	1	1
<b>C51 VULVA</b>					
<b>C51.9</b>	<b>Vulva</b>		<b>0</b>	<b>6</b>	<b>6</b>
M	8010/3	Carcinoma	0	1	1
M	8070/2	Squamous cell carcinoma in situ	0	1	1
M	8070/3	Squamous cell carcinoma	0	1	1
M	8071/3	Squamous cell carcinoma, keratinizing	0	1	1
M	8140/3	Adenocarcinoma	0	1	1
M	8542/3	Extramammary Paget disease	0	1	1
<b>C52 VAGINA</b>					
<b>C52.9</b>	<b>Vagina</b>		<b>0</b>	<b>3</b>	<b>3</b>
M	8010/3	Carcinoma	0	1	1
M	8070/3	Squamous cell carcinoma	0	1	1
M	8720/3	Malignant melanoma	0	1	1
<b>C53 CERVIX UTERI</b>					
<b>C53.0</b>	<b>Endocervix</b>		<b>0</b>	<b>23</b>	<b>23</b>
M	8070/3	Squamous cell carcinoma	0	2	2
M	8140/3	Adenocarcinoma	0	18	18
M	8380/3	Endometrioid adenocarcinoma	0	2	2

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8480/3	Mucinous adenocarcinoma	0	1	1
<b>C53.1</b>	<b>Exocervix</b>		<b>0</b>	<b>68</b>	<b>68</b>
M	8052/3	Papillary squamous cell carcinoma	0	1	1
M	8070/3	Squamous cell carcinoma	0	40	40
M	8071/3	Squamous cell carcinoma, keratinizing	0	7	7
M	8072/3	Squamous cell carcinoma, nonkeratinizing	0	17	17
M	8076/3	microinvasive squamous cell carcinoma	0	1	1
M	8084/3	Squamous cell carcinoma, clear cell type	0	1	1
M	8441/3	Serous adenocarcinoma	0	1	1
<b>C53.9</b>	<b>Cervix</b>		<b>0</b>	<b>18</b>	<b>18</b>
M	8010/3	Carcinoma	0	9	9
M	8013/3	Large cell neuroendocrine carcinoma	0	1	1
M	8070/3	Squamous cell carcinoma	0	1	1
M	8072/3	Squamous cell carcinoma, nonkeratinizing	0	1	1
M	8140/3	Adenocarcinoma	0	3	3
M	8310/3	Clear cell carcinoma	0	1	1
M	8560/3	Adenosquamous carcinoma	0	2	2
<b>C54 CORPUS UTERI</b>					
<b>C54.1</b>	<b>Endometrium</b>		<b>0</b>	<b>121</b>	<b>121</b>
M	8010/3	Carcinoma	0	1	1
M	8140/3	Adenocarcinoma	0	1	1
M	8246/3	Neuroendocrine carcinoma	0	1	1
M	8310/3	Clear cell carcinoma	0	3	3
M	8380/3	Endometrioid adenocarcinoma	0	94	94
M	8441/3	Serous adenocarcinoma	0	10	10
M	8800/3	Sarcoma	0	1	1
M	8930/3	Endometrial stromal sarcoma	0	2	2
M	8933/3	Adenosarcoma	0	1	1
M	8980/3	Carcinosarcoma	0	7	7
<b>C54.2</b>	<b>Myometrium</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8890/3	Leiomyosarcoma	0	1	1
<b>C54.9</b>	<b>Corpus uteri</b>		<b>0</b>	<b>3</b>	<b>3</b>
M	8010/3	Carcinoma	0	1	1
M	8380/3	Endometrioid adenocarcinoma	0	2	2
<b>C55 UTERUS</b>					
<b>C55.9</b>	<b>Uterus</b>		<b>0</b>	<b>5</b>	<b>5</b>
M	8800/3	Sarcoma	0	1	1
M	8890/3	Leiomyosarcoma	0	2	2
M	8930/3	Endometrial stromal sarcoma	0	1	1
M	9071/3	Yolk sac tumor	0	1	1



ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C56 OVARY</b>					
<b>C56.9</b>	<b>Ovary</b>		<b>0</b>	<b>86</b>	<b>86</b>
M	8010/3	Carcinoma	0	13	13
M	8076/3	microinvasive squamous cell carcinoma	0	1	1
M	8140/3	Adenocarcinoma	0	3	3
M	8246/3	Neuroendocrine carcinoma	0	1	1
M	8310/3	Clear cell carcinoma	0	12	12
M	8380/3	Endometrioid adenocarcinoma	0	15	15
M	8441/3	Serous adenocarcinoma	0	23	23
M	8480/3	Mucinous adenocarcinoma	0	9	9
M	8620/3	Granulosa cell tumor, malignant	0	1	1
M	8890/3	Leiomyosarcoma	0	1	1
M	9000/3	Malignant Brenner tumor	0	1	1
M	9060/3	Dysgerminoma	0	1	1
M	9080/3	Immature teratoma	0	4	4
M	9085/3	Mixed germ cell tumor	0	1	1
<b>C57 OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS</b>					
<b>C57.0</b>	<b>Fallopian tube</b>		<b>0</b>	<b>3</b>	<b>3</b>
M	8441/3	Serous adenocarcinoma	0	3	3
<b>C58 PLACENTA</b>					
<b>C58.9</b>	<b>Placenta</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	9100/3	Choriocarcinoma	0	2	2
<b>C60 PENIS</b>					
<b>C60.0</b>	<b>Prepuce</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C60.9</b>	<b>Penis</b>		<b>5</b>	<b>0</b>	<b>5</b>
M	8010/3	Carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	3	0	3
M	8076/3	microinvasive squamous cell carcinoma	1	0	1
<b>C61 PROSTATE GLAND</b>					
<b>C61.9</b>	<b>Prostate gland</b>		<b>373</b>	<b>0</b>	<b>373</b>
M	8010/3	Carcinoma	8	0	8
M	8140/3	Adenocarcinoma	343	0	343
M	8550/3	Acinar cell adenocarcinoma	22	0	22
<b>C62 TESTIS</b>					
<b>C62.9</b>	<b>Testis</b>		<b>5</b>	<b>0</b>	<b>5</b>
M	9061/3	Seminoma	1	0	1
M	9064/3	Germ cell tumor	1	0	1
M	9065/3	Germ cell tumor, nonseminomatous	2	0	2
M	9085/3	Mixed germ cell tumor	1	0	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
<b>C63 OTHER AND UNSPECIFIED MALE GENITAL ORGANS</b>					
<b>C63.1</b>	<b>Spermatic cord</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8858/3	Dedifferentiated liposarcoma	1	0	1
<b>C64 KIDNEY</b>					
<b>C64.9</b>	<b>Kidney</b>		<b>73</b>	<b>30</b>	<b>103</b>
M	8120/3	Transitional cell carcinoma	2	1	3
M	8130/3	Papillary transitional cell carcinoma	3	3	6
M	8310/3	Clear cell carcinoma	18	1	19
M	8312/3	Renal cell carcinoma	48	24	72
M	8317/3	Chromophobe cell renal carcinoma	1	0	1
M	8319/3	Renal carcinoma, collecting duct type	0	1	1
M	8960/3	Wilms tumor	1	0	1
<b>C65 RENAL PELVIS</b>					
<b>C65.9</b>	<b>Renal pelvis</b>		<b>5</b>	<b>8</b>	<b>13</b>
M	8120/3	Transitional cell carcinoma	5	8	13
<b>C66 URETER</b>					
<b>C66.9</b>	<b>Ureter</b>		<b>6</b>	<b>5</b>	<b>11</b>
M	8120/3	Transitional cell carcinoma	5	5	10
M	8130/3	Papillary transitional cell carcinoma	1	0	1
<b>C67 BLADDER</b>					
<b>C67.1</b>	<b>Dome of urinary bladder</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8120/3	Transitional cell carcinoma	1	0	1
<b>C67.4</b>	<b>Posterior wall of urinary bladder</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	8120/3	Transitional cell carcinoma	1	1	2
<b>C67.6</b>	<b>Ureteric orifice</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8120/3	Transitional cell carcinoma	1	0	1
<b>C67.9</b>	<b>Bladder</b>		<b>88</b>	<b>34</b>	<b>122</b>
M	8010/2	Carcinoma in situ	2	0	2
M	8010/3	Carcinoma	1	1	2
M	8070/3	Squamous cell carcinoma	0	1	1
M	8120/3	Transitional cell carcinoma	76	28	104
M	8130/2	Non-invasive papillary urothelial carcinoma, low grade	1	0	1
M	8130/3	Papillary transitional cell carcinoma	7	3	10
M	8140/3	Adenocarcinoma	1	0	1
M	8310/3	Clear cell carcinoma	0	1	1
<b>C68 OTHER AND UNSPECIFIED URINARY ORGANS</b>					
<b>C68.0</b>	<b>Urethra</b>		<b>2</b>	<b>0</b>	<b>2</b>
M	8070/3	Squamous cell carcinoma	1	0	1
M	8130/2	Non-invasive papillary urothelial carcinoma, low grade	1	0	1
<b>C69 EYE AND ADNEXA</b>					
<b>C69.0</b>	<b>Conjunctiva</b>		<b>2</b>	<b>1</b>	<b>3</b>
M	8070/3	Squamous cell carcinoma	2	0	2

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	8720/3	Malignant melanoma	0	1	1
<b>C69.2</b>	<b>Retina</b>		<b>7</b>	<b>7</b>	<b>14</b>
M	9510/3	Retinoblastoma	7	6	13
M	9513/3	Retinoblastoma, diffuse	0	1	1
<b>C69.3</b>	<b>Choroid</b>		<b>8</b>	<b>7</b>	<b>15</b>
M	8720/3	Malignant melanoma	8	7	15
<b>C69.4</b>	<b>Ciliary body</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8720/3	Malignant melanoma	0	1	1
<b>C69.6</b>	<b>Orbit</b>		<b>1</b>	<b>2</b>	<b>3</b>
M	8140/3	Adenocarcinoma	0	1	1
M	8720/3	Malignant melanoma	0	1	1
M	9120/3	Angiosarcoma	1	0	1
<b>C71 BRAIN</b>					
<b>C71.1</b>	<b>Frontal lobe</b>		<b>7</b>	<b>10</b>	<b>17</b>
M	8010/3	Carcinoma	0	1	1
M	9380/3	Glioma, malignant	2	3	5
M	9400/3	Astrocytoma	2	0	2
M	9411/3	Gemistocytic astrocytoma	0	1	1
M	9440/3	Glioblastoma	3	3	6
M	9530/3	Meningioma, malignant	0	2	2
<b>C71.2</b>	<b>Temporal lobe</b>		<b>10</b>	<b>5</b>	<b>15</b>
M	9380/3	Glioma, malignant	1	2	3
M	9382/3	Mixed glioma	1	0	1
M	9440/3	Glioblastoma	8	3	11
<b>C71.3</b>	<b>Parietal lobe</b>		<b>1</b>	<b>1</b>	<b>2</b>
M	9440/3	Glioblastoma	0	1	1
M	9442/3	Gliosarcoma	1	0	1
<b>C71.4</b>	<b>Occipital lobe</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	8010/3	Carcinoma	0	1	1
M	9391/3	Ependymoma	0	1	1
<b>C71.5</b>	<b>Ventricle</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9390/3	Choroid plexus carcinoma	1	0	1
<b>C71.6</b>	<b>Cerebellum</b>		<b>2</b>	<b>4</b>	<b>6</b>
M	9382/3	Mixed glioma	1	1	2
M	9391/3	Ependymoma	0	1	1
M	9470/3	Medulloblastoma	1	2	3
<b>C71.7</b>	<b>Brain stem</b>		<b>2</b>	<b>2</b>	<b>4</b>
M	9380/3	Glioma, malignant	2	1	3
M	9391/3	Ependymoma	0	1	1
<b>C71.9</b>	<b>Brain</b>		<b>1</b>	<b>4</b>	<b>5</b>
M	8806/3	Desmoplastic round cell tumor	0	1	1
M	9380/3	Glioma, malignant	1	0	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9382/3	Mixed glioma	0	1	1
M	9391/3	Ependymoma	0	2	2
<b>C72 SPINAL CORD, CRANIAL NERVES, AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM</b>					
<b>C72.0</b>	<b>Spinal cord</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	9391/3	Ependymoma	0	2	2
<b>C72.3</b>	<b>Optic nerve</b>		<b>0</b>	<b>2</b>	<b>2</b>
M	9380/3	Glioma, malignant	0	1	1
M	9530/3	Meningioma, malignant	0	1	1
<b>C73 THYROID GLAND</b>					
<b>C73.9</b>	<b>Thyroid gland</b>		<b>45</b>	<b>228</b>	<b>273</b>
M	8010/3	Carcinoma	0	1	1
M	8021/3	Anaplastic carcinoma	1	3	4
M	8260/3	Papillary carcinoma of thyroid	31	166	197
M	8290/3	Hurthle cell carcinoma	2	3	5
M	8330/3	Follicular carcinoma	3	10	13
M	8335/3	Follicular carcinoma, encapsulated	1	0	1
M	8340/3	Papillary carcinoma, follicular variant	0	14	14
M	8341/3	Papillary microcarcinoma	5	24	29
M	8343/3	Papillary carcinoma, encapsulate	0	4	4
M	8345/3	Medullary carcinoma of thyroid	2	3	5
<b>C74 ADRENAL GLAND</b>					
<b>C74.0</b>	<b>Cortex of adrenal gland</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8140/3	Adenocarcinoma	1	0	1
<b>C74.9</b>	<b>Adrenal gland</b>		<b>7</b>	<b>7</b>	<b>14</b>
M	8010/3	Carcinoma	1	0	1
M	8370/3	Adrenal cortical carcinoma	0	2	2
M	8700/3	Pheochromocytoma, malignant	0	1	1
M	9500/3	Neuroblastoma	6	4	10
<b>C75 OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES</b>					
<b>C75.0</b>	<b>Parathyroid gland</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8140/3	Adenocarcinoma	0	1	1
<b>C75.1</b>	<b>Pituitary gland</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9064/3	Germ cell tumor	1	0	1
<b>C75.3</b>	<b>Pineal gland</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9085/3	Mixed germ cell tumor	1	0	1
<b>C76 OTHER AND ILL-DEFINED SITES</b>					
<b>C76.0</b>	<b>Head, face of neck</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	8070/3	Squamous cell carcinoma	1	0	1
<b>C76.3</b>	<b>Pelvis</b>		<b>0</b>	<b>1</b>	<b>1</b>
M	8071/3	Squamous cell carcinoma, keratinizing	0	1	1
<b>C77 LYMPH NODES</b>					
<b>C77.0</b>	<b>Lymph node of head, face and neck</b>		<b>43</b>	<b>39</b>	<b>82</b>

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9590/3	Malignant lymphoma	2	1	3
M	9591/3	Malignant lymphoma, non-Hodgkin	3	3	6
M	9650/3	Hodgkin lymphoma	2	1	3
M	9652/3	Classical Hodgkin lymphoma, mixed cellularity	3	2	5
M	9659/3	Hodgkin lymphoma, nodular lymphocyte predominance	1	0	1
M	9663/3	Classical Hodgkin lymphoma, nodular sclerosis	1	1	2
M	9671/3	Malignant lymphoma, lymphoplasmacytic	0	2	2
M	9673/3	Mantle cell lymphoma	1	2	3
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	19	17	36
M	9684/3	Plasmablastic lymphoma	1	1	2
M	9690/3	Follicular lymphoma	1	2	3
M	9698/3	Follicular lymphoma, grade 3	3	0	3
M	9699/3	Marginal zone B-cell lymphoma	2	6	8
M	9702/3	Peripheral T-cell lymphoma	2	0	2
M	9705/3	Angioimmunoblastic T-cell lymphoma	1	0	1
M	9709/3	Cutaneous T-cell lymphoma	0	1	1
M	9719/3	NK/T-cell lymphoma, nasal and nasal-type	1	0	1
<b>C77.1</b>	<b>Intrathoracic lymph nodes</b>		<b>7</b>	<b>10</b>	<b>17</b>
M	9591/3	Malignant lymphoma, non-Hodgkin	1	0	1
M	9650/3	Hodgkin lymphoma	0	2	2
M	9663/3	Classical Hodgkin lymphoma, nodular sclerosis	0	1	1
M	9673/3	Mantle cell lymphoma	1	0	1
M	9679/3	Primary mediastinal large B-cell lymphoma	0	1	1
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	1	6	7
M	9687/3	Burkitt lymphoma	1	0	1
M	9699/3	Marginal zone B-cell lymphoma	3	0	3
<b>C77.2</b>	<b>Intra-abdominal lymph nodes</b>		<b>29</b>	<b>23</b>	<b>52</b>
M	9591/3	Malignant lymphoma, non-Hodgkin	0	2	2
M	9652/3	Classical Hodgkin lymphoma, mixed cellularity	1	0	1
M	9673/3	Mantle cell lymphoma	2	1	3
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	15	12	27
M	9687/3	Burkitt lymphoma	1	0	1
M	9691/3	Follicular lymphoma, grade 2	0	2	2
M	9695/3	Follicular lymphoma, grade 1	3	0	3
M	9699/3	Marginal zone B-cell lymphoma	3	6	9
M	9702/3	Peripheral T-cell lymphoma	3	0	3
M	9708/3	Subcutaneous panniculitis like T-cell lymphoma	1	0	1
<b>C77.3</b>	<b>Lymph node of axilla or arm</b>		<b>8</b>	<b>9</b>	<b>17</b>
M	9591/3	Malignant lymphoma, non-Hodgkin	3	1	4
M	9670/3	Malignant lymphoma, lymphocytic	0	1	1
M	9673/3	Mantle cell lymphoma	0	1	1

ICD-O SITE AND HISTOPATHOLOGY			Male	Female	Total
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	3	6	9
M	9690/3	Follicular lymphoma	1	0	1
M	9714/3	Anaplastic large cell lymphoma	1	0	1
<b>C77.4</b>	<b>Lymph nodes of inguinal region or leg</b>		<b>3</b>	<b>7</b>	<b>10</b>
M	9591/3	Malignant lymphoma, non-Hodgkin	1	2	3
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	1	4	5
M	9705/3	Angioimmunoblastic T-cell lymphoma	1	0	1
M	9714/3	Anaplastic large cell lymphoma	0	1	1
<b>C77.5</b>	<b>Pelvic lymph nodes</b>		<b>1</b>	<b>3</b>	<b>4</b>
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	1	3	4
<b>C77.8</b>	<b>Lymph nodes of multiple regions</b>		<b>1</b>	<b>0</b>	<b>1</b>
M	9709/3	Cutaneous T-cell lymphoma	1	0	1
<b>C77.9</b>	<b>Lymph node</b>		<b>17</b>	<b>15</b>	<b>32</b>
M	9590/3	Malignant lymphoma	0	2	2
M	9591/3	Malignant lymphoma, non-Hodgkin	4	2	6
M	9651/3	Hodgkin lymphoma, lymphocyte-rich	1	0	1
M	9673/3	Mantle cell lymphoma	1	0	1
M	9680/3	Diffuse large B-cell lymphoma (DLBCL)	3	6	9
M	9687/3	Burkitt lymphoma	1	0	1
M	9699/3	Marginal zone B-cell lymphoma	5	3	8
M	9708/3	Subcutaneous panniculitis like T-cell lymphoma	2	0	2
M	9714/3	Anaplastic large cell lymphoma	0	1	1
M	9719/3	T/NK-cell lymphoma	0	1	1
<b>C80 UNKNOWN PRIMARY SITE</b>					
<b>C80.9</b>	<b>Unknown primary site</b>		<b>12</b>	<b>8</b>	<b>20</b>
M	8010/3	Carcinoma	5	3	8
M	8041/3	Small cell carcinoma	1	0	1
M	8070/3	Squamous cell carcinoma	1	0	1
M	8082/3	Lymphoepithelial carcinoma	0	1	1
M	8140/3	Adenocarcinoma	2	4	6
M	8246/3	Neuroendocrine carcinoma	1	0	1
M	8480/3	Mucinous adenocarcinoma	1	0	1
M	8936/3	GIST, malignant	1	0	1

**CHAPTER V**  
**THE MOST COMMON CANCER SITES**

**BREAST**

**COLORECTAL**

**LUNG AND BRONCHUS**

**PROSTATE GLAND**

**LIVER AND INTRAHEPATIC BILE DUCTS**

**HEMATOPOIETIC AND RETICULOENDOTHELIAL**

**THYROID GLAND**

**CHILDHOOD CANCER**


## BREAST

**Table 5.1** Age and gender of breast cancer.

Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	56.5 (12.5)
Median and range age at diagnosis	56 (20:95)
% of the patient is lower than 18 year of age at diagnosis	0.0%
<b>Gender</b>	
Male	2 (0.2%)
Female	884 (99.8%)
Sex ratio (male: female)	0.0:1


**Table 5.2** Most valid method of diagnosis for breast cancer.

Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Clinical investigation/imaging	0	0.0	2	0.2	2	0.2
Histology or metastasis	0	0.0	1	0.1	1	0.1
Histology of primary	2	100.0	881	99.7	883	99.7
<b>Total</b>	<b>2</b>	<b>100.0</b>	<b>884</b>	<b>100.0</b>	<b>886</b>	<b>100.0</b>




**Figure 5.1** Age at diagnosis of breast cancer, 2022, by sex.





**Figure 5.2** Distribution of staging for breast cancer. (%)



**Figure 5.3** Distribution of metastasis for breast cancer.


## COLORECTAL

**Table 5.3** Age and gender of colorectal cancer.


Special Notes	
Age	
Mean and standard deviation age at diagnosis (years)	64.9 (12.8)
Median and range age at diagnosis	66 (13:93)
% of the patient is lower than 18 year of age at diagnosis	0.2%
Gender	
Male	314 (54.6%)
Female	261 (45.4%)
Sex ratio (male: female)	1.20:1

**Table 5.4** Most valid method of diagnosis for colorectal cancer.


Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Clinical investigation/imaging	1	0.3	0	0.0	1	0.2
Histology of primary	313	99.7	261	100.0	574	99.8
<b>Total</b>	<b>314</b>	<b>100.0</b>	<b>261</b>	<b>100.0</b>	<b>575</b>	<b>100.0</b>



**Figure 5.4** Age at diagnosis of colorectal cancer, 2022, by sex.



**Figure 5.5** Distribution of staging for colorectal cancer.



**Figure 5.6** Distribution of metastasis for colorectal cancer.


## BRONCHUS AND LUNG

**Table 5.5** Age and gender of lung cancer.


Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	67.1 (10.9)
Median and range age at diagnosis	67 (17:91)
% of the patient is lower than 18 year of age at diagnosis	0.2%
<b>Gender</b>	
Male	224 (52.2%)
Female	205 (47.8%)
Sex ratio (male: female)	1.09:1

**Table 5.6** Most valid method of diagnosis for lung cancer.


Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Clinical investigation/imaging	0	0.0	1	0.5	1	0.2
Histology of primary	224	100.0	204	99.5	428	99.8
<b>Total</b>	<b>224</b>	<b>100.0</b>	<b>205</b>	<b>100.0</b>	<b>429</b>	<b>100.0</b>



**Figure 5.7** Age at diagnosis of lung cancer, 2022, by sex.



**Figure 5.8** Distribution of staging for lung cancer.



**Figure 5.9** Distribution of metastasis for lung cancer.


## PROSTATE GLAND

**Table 5.7** Age and gender of prostate cancer.


Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	71.1 (7.9)
Median and range age at diagnosis	71 (48:93)
% of the patient is lower than 18 year of age at diagnosis	0.00%
<b>Gender</b>	
Male	373 (100.0%)
Sex ratio (male: female)	1:00

**Table 5.8** Most valid method of diagnosis for prostate cancer.


Basis of diagnosis	Male		Total	
	N	%	N	%
Clinical investigation/imaging	2	0.5	2	0.5
Histology of primary	371	99.5	371	99.5
<b>Total</b>	<b>373</b>	<b>100.0</b>	<b>373</b>	<b>100.0</b>



**Figure 5.10** Age at diagnosis of prostate cancer, 2022.



**Figure 5.11** Distribution of staging for prostate cancer.



**Figure 5.12** Distribution of metastasis for prostate cancer.


## LIVER AND INTRAHEPATIC BILE DUCTS

**Table 5.9** Age and gender of liver and bile duct cancer.

Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	64.5 (13.0)
Median and range age at diagnosis	64 (1:98)
% of the patient is lower than 18 year of age at diagnosis	1.3%
<b>Gender</b>	
Male	205 (66.8%)
Female	102 (33.2%)
Sex ratio (male: female)	2.0:1


**Table 5.10** Most valid method of diagnosis for liver and bile duct cancer.

Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Clinical investigation/imaging	68	33.2	22	21.6	90	29.3
Histology of metastasis	1	0.5	0	0.0	1	0.3
Histology of primary	136	66.3	80	78.4	216	70.4
<b>Total</b>	<b>205</b>	<b>100.0</b>	<b>102</b>	<b>100.0</b>	<b>307</b>	<b>100.0</b>




**Figure 5.13** Age at diagnosis of liver and bile duct cancer, 2022 by sex.





**Figure 5.14** Distribution of staging for liver and bile duct cancer.



**Figure 5.15** Distribution of metastasis for liver and bile duct cancer.


## HEMATOPOIETIC AND RETICULOENDOTHELIAL

**Table 5.11** Age and gender of Hematopoietic and Reticuloendothelial.


Special Notes	
Age	
Mean and standard deviation age at diagnosis (years)	56.5 (24.3)
Median and range age at diagnosis	63 (0:98)
% of the patient is lower than 18 year of age at diagnosis	12.5%
Gender	
Male	152 (54.3%)
Female	128 (45.7%)
Sex ratio (male: female)	1.2:1

**Table 5.12** Most valid method of diagnosis for Hematopoietic and Reticuloendothelial.


Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Histology of primary	152	100.0	128	100.0	280	100.0
<b>Total</b>	<b>152</b>	<b>100.0</b>	<b>128</b>	<b>100.0</b>	<b>280</b>	<b>100.0</b>



**Figure 5.16** Age at diagnosis of Hematopoietic and Reticuloendothelial, 2022 by sex.



**Figure 5.17** Distribution of staging for Hematopoietic and Reticuloendothelial.



**Figure 5.18** Distribution of metastasis for Hematopoietic and Reticuloendothelial.


## THYROID GLAND

**Table 5.13** Age and gender of thyroid gland cancer.


Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	50.9 (16.3)
Median and range age at diagnosis	52 (9:93)
% of the patient is lower than 18 year of age at diagnosis	1.8%
<b>Gender</b>	
Male	45 (16.5%)
Female	228 (83.5%)
Sex ratio (male: female)	0.2:1

**Table 5.14** Most valid method of diagnosis for thyroid gland cancer.


Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Histology of primary	45	100.0	228	100.0	273	100.0
<b>Total</b>	<b>45</b>	<b>100.0</b>	<b>228</b>	<b>100.0</b>	<b>273</b>	<b>100.0</b>



**Figure 5.19** Age at diagnosis of thyroid gland cancer, 2022, by sex.



**Figure 5.20** Distribution of staging for thyroid gland cancer.



**Figure 5.21** Distribution of metastasis for thyroid gland cancer.


## CHILDHOOD CANCER

**Table 5.15** Age and gender of childhood cancer.

Special Notes	
<b>Age</b>	
Mean and standard deviation age at diagnosis (years)	6.9 (5.2)
Median and range age at diagnosis	5.0 (0:17)
% of the patient is lower than 18 year of age at diagnosis	100.0%
<b>Gender</b>	
Male	57 (51.8%)
Female	53 (48.2%)
Sex ratio (male: female)	1.07:1

**Table 5.16** Most valid method of diagnosis for childhood cancer.


Basis of diagnosis	Male		Female		Total	
	N	%	N	%	N	%
Histology of primary	57	100.0	53	100.0	110	100.0
<b>Total</b>	<b>57</b>	<b>100.0</b>	<b>53</b>	<b>100.0</b>	<b>110</b>	<b>100.0</b>



**Figure 5.22** Number of childhood cancer by ICCC group, age <18, both sexes.

**Table 5.17** Number of cancer in childhood by ICCC group, age <18 both sexes.

ICCC GROUP	Male					Female					M:F	%MV
	≤4	5-9	10-14	15-19	Total	≤4	5-9	10-14	15-19	Total		
Leukemia - I	7	5	1	4	17	7	8	3	0	18	0.9	100.0
Lymphoma - II	2	3	3	1	9	0	2	2	0	4	2.3	100.0
Brain/CNS - III	3	2	0	1	6	4	1	2	0	7	0.9	100.0
Sympathetics NER. - IV	5	2	0	0	7	1	3	0	0	4	1.8	100.0
Retinoblastoma - V	7	0	0	0	7	4	2	0	0	6	1.2	100.0
Renal - VI	1	0	0	0	1	0	0	0	0	0	0.0	100.0
Hepatic - VII	1	0	0	0	1	1	0	2	0	3	0.3	100.0
Malignant bone - VIII	0	0	0	0	0	1	0	1	0	2	0.0	100.0
Soft Tissue - IX	0	0	2	2	4	2	0	0	2	4	1.0	100.0
Germ Cell - X	1	0	0	1	2	0	0	1	0	1	2.0	100.0
Carcinomas - XI	0	2	1	0	3	0	1	1	2	4	0.8	100.0
<b>Total</b>	<b>27</b>	<b>14</b>	<b>7</b>	<b>9</b>	<b>57</b>	<b>20</b>	<b>17</b>	<b>12</b>	<b>4</b>	<b>53</b>	<b>11.1</b>	<b>100.0</b>




**Figure 5.23** Number of cases of all childhood cancer by ICCC and Age Group, both Sexes.

## CHAPTER VI

## DISTRIBUTION BY REGIONAL OF THAILAND

**Table 6.1** Number of cancer cases by region, 2022.

Region	Number	%
Bangkok	2,209	45.6
North	51	1.1
Northeast	246	5.1
Central	1,571	32.4
East	358	7.4
West	172	3.6
South	242	5.0
<b>Total</b>	<b>4,849</b>	<b>100.0</b>

**Figure 6.1** Distribution of region, 2022. (%)



**Table 6.2** Number of cancer cases by topography and region, 2022.

Topography	Bangkok	North	Northeast	Central	East	West	South	Total
C00 Lip	1	1	0	1	1	0	0	4
C01 Base of Tongue	0	0	3	1	1	0	2	7
C02 Other and unspecified part of Tongue	14	0	0	11	6	1	1	33
C03 Gum	3	0	0	2	0	0	0	5
C04 Floor of Mouth	0	0	0	2	1	0	0	3
C05 Palate	3	0	1	1	1	1	1	8
C06 Other and unspecified part of Mouth	3	0	0	2	1	0	0	6
C07 Parotid gland	3	0	0	3	1	1	0	8
C08 Other and unspecified major salivary glands	0	0	0	1	0	0	1	2
C09 Tonsil	7	1	1	8	1	0	1	19
C10 Oropharynx	0	0	1	0	0	1	0	2
C11 Nasopharynx	27	2	5	17	4	1	4	60
C12 Pyriform sinus	1	0	0	4	1	0	1	7
C13 Hypopharynx	2	0	0	0	0	0	0	2
C15 Esophagus	14	0	1	10	6	0	5	36
C16 Stomach	36	0	3	32	4	1	7	83
C17 Small Intestine	5	0	1	3	1	0	1	11
C18-C20 Colorectal	265	7	25	191	43	22	22	575
C21 Anus and Anal canal	3	0	0	2	0	0	0	5
C22 Liver and Intrahepatic bile ducts	127	7	23	101	23	12	14	307
C23 Gallbladder	6	0	0	1	1	1	0	9
C24 Other and unspecified parts of biliary tract	7	0	1	7	2	0	1	18
C25 Pancreas	33	1	3	18	3	1	3	62
C30 Nasal Cavity	4	1	2	4	1	0	1	13
C31 Accessory sinuses	0	0	1	2	2	1	0	6
C32 Larynx	12	2	1	15	3	0	2	35
C34 Bronchus and Lung	218	4	18	122	27	17	23	429
C37 Thymus	4	0	1	6	1	0	1	13
C38 Heart, Mediastinum	6	0	0	2	1	0	0	9
C40 Bones, Joints and articular cartilage of limbs	4	0	0	2	0	0	0	6
C41 Bones, Joints and articular cartilage of other and unspecified sites	5	0	1	4	1	0	1	12
C42 Hematopoietic and Reticuloendothelial systems	131	3	20	96	20	5	5	280
C44 Skin	108	3	6	74	14	8	10	223
C47 Peripheral nerves and autonomic nervous system	0	0	0	1	0	0	0	1
C48 Retroperitoneum and Peritoneum	6	0	0	1	2	2	1	12

Topography	Bangkok	North	Northeast	Central	East	West	South	Total
C49 Connective, Subcutaneous and Other soft tissues	27	0	6	9	7	3	1	53
C50 Breast	410	4	35	301	67	30	39	886
C51 Vulva	2	0	0	4	0	0	0	6
C52 Vagina	1	0	0	2	0	0	0	3
C53 Cervix uteri	49	1	4	28	11	9	7	109
C54 Corpus uteri	58	0	5	37	8	7	10	125
C55 Uterus	3	0	1	1	0	0	0	5
C56 Ovary	38	0	6	33	6	0	3	86
C57 Other and Unspecified female genital organs	2	0	0	1	0	0	0	3
C58 Placenta	1	0	0	1	0	0	0	2
C60 Penis	3	1	1	1	0	0	0	6
C61 Prostate gland	181	7	15	124	21	14	11	373
C62 Testis	3	0	0	2	0	0	0	5
C63 Other and Unspecified male genital organs	1	0	0	0	0	0	0	1
C64 Kidney	57	0	3	26	7	4	6	103
C65 Renal pelvis	8	0	0	3	0	1	1	13
C66 Ureter	7	0	0	2	1	0	1	11
C67 Bladder	68	0	3	37	6	6	6	126
C68 Other and Unspecified urinary organs	0	0	0	0	0	1	1	2
C69 Eye and Adnexa	7	0	1	20	4	1	3	36
C71 Brain	17	1	4	15	6	4	5	52
C72 Spinal cord	0	0	3	0	0	1	0	4
C73 Thyroid gland	107	1	22	84	23	10	26	273
C74 Adrenal gland	6	1	2	6	0	0	0	15
C75 Other endocrine glands	3	0	0	0	0	0	0	3
C76 Other and ill-defined sites	2	0	0	0	0	0	0	2
C77 Lymph nodes	84	2	16	83	16	4	10	215
C80 Unknown primary site	6	1	1	4	2	2	4	20
<b>Total</b>	<b>2,209</b>	<b>51</b>	<b>246</b>	<b>1,571</b>	<b>358</b>	<b>172</b>	<b>242</b>	<b>4,849</b>

**Table 6.3** Distribution of topography in Bangkok, 2022.

Topography	Number	%
C00 Lip	1	0.1
C02 Other and unspecified part of Tongue	14	0.6
C03 Gum	3	0.1
C05 Palate	3	0.1
C06 Other and unspecified part of Mouth	3	0.1
C07 Parotid gland	3	0.1
C09 Tonsil	7	0.3
C11 Nasopharynx	27	1.2
C12 Pyriform sinus	1	0.1
C13 Hypopharynx	2	0.1
C15 Esophagus	14	0.6
C16 Stomach	36	1.6
C17 Small Intestine	5	0.2
C18-C20 Colorectal	265	12.0
C21 Anus and Anal canal	3	0.1
C22 Liver and Intrahepatic bile ducts	127	5.8
C23 Gallbladder	6	0.3
C24 Other and unspecified parts of biliary tract	7	0.3
C25 Pancreas	33	1.5
C30 Nasal Cavity	4	0.2
C32 Larynx	12	0.5
C34 Bronchus and Lung	218	9.9
C37 Thymus	4	0.2
C38 Heart, Mediastinum	6	0.3
C40 Bones, Joints and articular cartilage of limbs	4	0.2
C41 Bones, Joints and articular cartilage of other and unspecified sites	5	0.2
C42 Hematopoietic and Reticuloendothelial systems	131	5.9
C44 Skin	108	4.9
C48 Retroperitoneum and Peritoneum	6	0.3
C49 Connective, Subcutaneous and Other soft tissues	27	1.2
C50 Breast	410	18.6
C51 Vulva	2	0.1
C52 Vagina	1	0.1
C53 Cervix uteri	49	2.2
C54 Corpus uteri	58	2.6
C55 Uterus	3	0.1
C56 Ovary	38	1.7
C57 Other and Unspecified female genital organs	2	0.1
C58 Placenta	1	0.1
C60 Penis	3	0.1
C61 Prostate gland	181	8.2
C62 Testis	3	0.1
C63 Other and Unspecified male genital organs	1	0.1
C64 Kidney	57	2.6
C65 Renal pelvis	8	0.4

Topography	Number	%
C66 Ureter	7	0.3
C67 Bladder	68	3.1
C69 Eye and Adnexa	7	0.3
C71 Brain	17	0.8
C73 Thyroid gland	107	4.8
C74 Adrenal gland	6	0.3
C75 Other endocrine glands	3	0.1
C76 Other and ill-defined sites	2	0.1
C77 Lymph nodes	84	3.8
C80 Unknown primary site	6	0.3
<b>Total</b>	<b>2,209</b>	<b>100.0</b>





Figure 6.2 Leading cancer in Bangkok, 2022.

**Table 6.6** Distribution of topography in North, 2022.


Topography	Number	%
C00 Lip	1	2.0
C09 Tonsil	1	2.0
C11 Nasopharynx	2	3.9
C18-C20 Colorectal	7	13.7
C22 Liver and Intrahepatic bile ducts	7	13.7
C25 Pancreas	1	2.0
C30 Nasal Cavity	1	2.0
C32 Larynx	2	3.9
C34 Bronchus and Lung	4	7.8
C42 Hematopoietic and Reticuloendothelial systems	3	5.9
C44 Skin	3	5.9
C50 Breast	4	7.8
C53 Cervix uteri	1	2.0
C60 Penis	1	2.0
C61 Prostate gland	7	13.7
C71 Brain	1	2.0
C73 Thyroid gland	1	2.0
C74 Adrenal gland	1	2.0
C77 Lymph nodes	2	3.9
C80 Unknown primary site	1	2.0
<b>Total</b>	<b>51</b>	<b>100.0</b>



**Figure 6.5** Leading cancer in North, 2022.

**Table 6.7** Distribution of topography in North-East, 2022.

Topography	Number	%
C01 Base of Tongue	3	1.2
C05 Palate	1	0.4
C09 Tonsil	1	0.4
C10 Oropharynx	1	0.4
C11 Nasopharynx	5	2.0
C15 Esophagus	1	0.4
C16 Stomach	3	1.2
C17 Small Intestine	1	0.4
C18-C20 Colorectal	25	10.2
C22 Liver and Intrahepatic bile ducts	23	9.4
C24 Other and unspecified parts of biliary tract	1	0.4
C25 Pancreas	3	1.2
C30 Nasal Cavity	2	0.8
C31 Accessory sinuses	1	0.4
C32 Larynx	1	0.4
C34 Bronchus and Lung	18	7.3
C37 Thymus	1	0.4
C41 Bones, Joints and articular cartilage of other and unspecified sites	1	0.4
C42 Hematopoietic and Reticuloendothelial systems	20	8.1
C44 Skin	6	2.4
C49 Connective, Subcutaneous and Other soft tissues	6	2.4
C50 Breast	35	14.2
C53 Cervix uteri	4	1.6
C54 Corpus uteri	5	2.0
C55 Uterus	1	0.4
C56 Ovary	6	2.4
C60 Penis	1	0.4
C61 Prostate gland	15	6.1
C64 Kidney	3	1.2
C67 Bladder	3	1.2
C69 Eye and Adnexa	1	0.4
C71 Brain	4	1.6
C72 Spinal cord	3	1.2
C73 Thyroid gland	22	8.9
C74 Adrenal gland	2	0.8
C77 Lymph nodes	16	6.5
C80 Unknown primary site	1	0.4
<b>Total</b>	<b>246</b>	<b>100.0</b>




**Figure 6.6** Leading cancer in North-East, 2022.

**Table 6.4** Distribution of topography in Central, 2022.

Topography	Number	%
C00 Lip	1	0.1
C01 Base of Tongue	1	0.1
C02 Other and unspecified part of Tongue	11	0.7
C03 Gum	2	0.1
C04 Floor of Mouth	2	0.1
C05 Palate	1	0.1
C06 Other and unspecified part of Mouth	2	0.1
C07 Parotid gland	3	0.2
C08 Other and unspecified major salivary glands	1	0.1
C09 Tonsil	8	0.5
C11 Nasopharynx	17	1.1
C12 Pyriform sinus	4	0.3
C15 Esophagus	10	0.6
C16 Stomach	32	2.0
C17 Small Intestine	3	0.2
C18-C20 Colorectal	191	12.2
C21 Anus and Anal canal	2	0.1
C22 Liver and Intrahepatic bile ducts	101	6.4
C23 Gallbladder	1	0.1
C24 Other and unspecified parts of biliary tract	7	0.5
C25 Pancreas	18	1.2
C30 Nasal Cavity	4	0.3
C31 Accessory sinuses	2	0.1
C32 Larynx	15	1.0
C34 Bronchus and Lung	122	7.8
C37 Thymus	6	0.4
C38 Heart, Mediastinum	2	0.1
C40 Bones, Joints and articular cartilage of limbs	2	0.1
C41 Bones, Joints and articular cartilage of other and unspecified sites	4	0.3
C42 Hematopoietic and Reticuloendothelial systems	96	6.1
C44 Skin	74	4.7
C47 Peripheral nerves and autonomic nervous system	1	0.1
C48 Retroperitoneum and Peritoneum	1	0.1
C49 Connective, Subcutaneous and Other soft tissues	9	0.6
C50 Breast	301	19.2
C51 Vulva	4	0.3
C52 Vagina	2	0.1
C53 Cervix uteri	28	1.8
C54 Corpus uteri	37	2.4
C55 Uterus	1	0.1
C56 Ovary	33	2.1
C57 Other and Unspecified female genital organs	1	0.1




Topography	Number	%
C58 Placenta	1	0.1
C60 Penis	1	0.1
C61 Prostate gland	124	7.9
C62 Testis	2	0.1
C64 Kidney	26	1.7
C65 Renal pelvis	3	0.2
C66 Ureter	2	0.1
C67 Bladder	37	2.4
C69 Eye and Adnexa	20	1.3
C71 Brain	15	1.0
C73 Thyroid gland	84	5.4
C74 Adrenal gland	6	0.4
C77 Lymph nodes	83	5.3
C80 Unknown primary site	4	0.3
<b>Total</b>	<b>1,571</b>	<b>100.0</b>



**Figure 6.3** Leading cancer in Central, 2022.

**Table 6.5** Distribution of topography in East, 2022.


Topography	Number	%
C00 Lip	1	0.3
C01 Base of Tongue	1	0.3
C02 Other and unspecified part of Tongue	6	1.7
C04 Floor of Mouth	1	0.3
C05 Palate	1	0.3
C06 Other and unspecified part of Mouth	1	0.3
C07 Parotid gland	1	0.3
C09 Tonsil	1	0.3
C11 Nasopharynx	4	1.1
C12 Pyriform sinus	1	0.3
C15 Esophagus	6	1.7
C16 Stomach	4	1.1
C17 Small Intestine	1	0.3
C18-C20 Colorectal	43	12.0
C22 Liver and Intrahepatic bile ducts	23	6.4
C23 Gallbladder	1	0.3
C24 Other and unspecified parts of biliary tract	2	0.6
C25 Pancreas	3	0.8
C30 Nasal Cavity	1	0.3
C31 Accessory sinuses	2	0.6
C32 Larynx	3	0.8
C34 Bronchus and Lung	27	7.5
C37 Thymus	1	0.3
C38 Heart, Mediastinum	1	0.3
C41 Bones, Joints and articular cartilage of other and unspecified sites	1	0.3
C42 Hematopoietic and Reticuloendothelial systems	20	5.6
C44 Skin	14	3.9
C48 Retroperitoneum and Peritoneum	2	0.6
C49 Connective, Subcutaneous and Other soft tissues	7	2.0
C50 Breast	67	18.7
C53 Cervix uteri	11	3.1
C54 Corpus uteri	8	2.2
C56 Ovary	6	1.7
C61 Prostate gland	21	5.9
C64 Kidney	7	2.0
C66 Ureter	1	0.3
C67 Bladder	6	1.7
C69 Eye and Adnexa	4	1.1
C71 Brain	6	1.7
C73 Thyroid gland	23	6.4
C77 Lymph nodes	16	4.5
C80 Unknown primary site	2	0.6
<b>Total</b>	<b>358</b>	<b>100.0</b>



**Figure 6.4** Leading cancer in East, 2022

**Table 6.9** Distribution of topography in West, 2022.


Topography	Number	%
C02 Other and unspecified part of Tongue	1	0.6
C05 Palate	1	0.6
C07 Parotid gland	1	0.6
C10 Oropharynx	1	0.6
C11 Nasopharynx	1	0.6
C16 Stomach	1	0.6
C18-C20 Colorectal	22	12.8
C22 Liver and Intrahepatic bile ducts	12	7.0
C23 Gallbladder	1	0.6
C25 Pancreas	1	0.6
C31 Accessory sinuses	1	0.6
C34 Bronchus and Lung	17	9.9
C42 Hematopoietic and Reticuloendothelial systems	5	2.9
C44 Skin	8	4.7
C48 Retroperitoneum and Peritoneum	2	1.2
C49 Connective, Subcutaneous and Other soft tissues	2	1.2
C50 Breast	30	17.4
C53 Cervix uteri	9	5.2
C54 Corpus uteri	7	4.1
C61 Prostate gland	14	8.1
C64 Kidney	4	2.3
C65 Renal pelvis	1	0.6
C67 Bladder	6	3.5
C68 Other and Unspecified urinary organs	1	0.6
C69 Eye and Adnexa	1	0.6
C71 Brain	4	2.3
C72 Spinal cord	1	0.6
C73 Thyroid gland	10	5.8
C74 Adrenal gland	1	0.6
C77 Lymph nodes	4	2.3
C80 Unknown primary site	2	1.2
<b>Total</b>	<b>172</b>	<b>100.0</b>



**Figure 6.8** Leading cancer in West, 2022.

**Table 6.8** Distribution of topography in South, 2022.


Topography	Number	%
C01 Base of Tongue	2	0.8
C02 Other and unspecified part of Tongue	1	0.4
C05 Palate	1	0.4
C08 Other and unspecified major salivary glands	1	0.4
C09 Tonsil	1	0.4
C11 Nasopharynx	4	1.7
C12 Pyriform sinus	1	0.4
C15 Esophagus	5	2.1
C16 Stomach	7	2.9
C17 Small Intestine	1	0.4
C18-C20 Colorectal	22	9.1
C22 Liver and Intrahepatic bile ducts	14	5.8
C24 Other and unspecified parts of biliary tract	1	0.4
C25 Pancreas	3	1.2
C30 Nasal Cavity	1	0.4
C32 Larynx	2	0.8
C34 Bronchus and Lung	23	9.5
C37 Thymus	1	0.4
C41 Bones, Joints and articular cartilage of other and unspecified sites	1	0.4
C42 Hematopoietic and Reticuloendothelial systems	5	2.1
C44 Skin	10	4.1
C48 Retroperitoneum and Peritoneum	1	0.4
C49 Connective, Subcutaneous and Other soft tissues	1	0.4
C50 Breast	39	16.1
C53 Cervix uteri	7	2.9
C54 Corpus uteri	10	4.1
C56 Ovary	3	1.2
C61 Prostate gland	11	4.6
C64 Kidney	6	2.5
C65 Renal pelvis	1	0.4
C66 Ureter	1	0.4
C67 Bladder	6	2.5
C68 Other and Unspecified urinary organs	1	0.4
C69 Eye and Adnexa	3	1.2
C71 Brain	5	2.1
C73 Thyroid gland	26	10.7
C77 Lymph nodes	10	4.1
C80 Unknown primary site	4	1.7
<b>Total</b>	<b>242</b>	<b>100.0</b>



**Figure 6.7** Leading cancer in South, 2022.

**Table 6.10** Distribution of staging for breast cancer of region, 2022.


Region	Staging							
	Stage 0	Stage I	Stage II	Stage III	Stage IV	Recurrent	Unknown	Total
Bangkok	38	105	123	42	33	6	63	410
North	0	1	1	0	0	1	1	4
Northeast	0	11	11	9	1	0	3	35
Central	24	70	101	46	17	3	40	301
East	1	16	26	10	8	1	5	67
West	2	6	9	5	2	2	4	30
South	3	9	15	2	5	2	3	39
<b>Total</b>	<b>68</b>	<b>218</b>	<b>286</b>	<b>114</b>	<b>66</b>	<b>15</b>	<b>119</b>	<b>886</b>

**Figure 6.9** Distribution of staging for breast cancer of region, 2022.



**Table 6.11** Distribution of staging for colorectal cancer of region, 2022.


Region	Staging							Total
	Stage 0	Stage I	Stage II	Stage III	Stage IV	Recurrent	Unknown	
Bangkok	0	32	44	87	78	4	20	265
North	0	1	1	2	3	0	0	7
Northeast	0	1	4	8	10	0	2	25
Central	1	17	41	62	45	2	23	191
East	0	2	10	10	14	2	5	43
West	0	2	2	10	6	0	2	22
South	0	3	3	5	7	0	4	22
<b>Total</b>	<b>1</b>	<b>58</b>	<b>105</b>	<b>184</b>	<b>163</b>	<b>8</b>	<b>56</b>	<b>575</b>



**Figure 6.10** Distribution of staging for colorectal cancer of region, 2022.


**Table 6.12** Distribution of staging for lung cancer of region, 2022.

Region	Staging						
	Stage I	Stage II	Stage III	Stage IV	Recurrent	Unknown	Total
Bangkok	41	13	27	112	3	22	218
North	0	0	1	2	0	1	4
Northeast	1	1	2	13	0	1	18
Central	33	3	18	63	0	5	122
East	2	4	6	14	0	1	27
West	2	0	2	13	0	0	17
South	1	1	3	18	0	0	23
<b>Total</b>	<b>80</b>	<b>22</b>	<b>59</b>	<b>235</b>	<b>3</b>	<b>30</b>	<b>429</b>

**Figure 6.11** Distribution of staging for lung cancer of region, 2022.

**Table 6.13** Distribution of staging for prostate cancer of region, 2022.


Region	Staging						
	Stage I	Stage II	Stage III	Stage IV	Recurrent	Unknown	Total
Bangkok	3	4	8	29	2	135	181
North	0	0	1	0	0	6	7
Northeast	0	0	0	1	0	14	15
Central	2	2	4	24	0	92	124
East	0	0	0	3	0	18	21
West	0	0	0	3	0	11	14
South	0	0	0	1	0	10	11
<b>Total</b>	<b>5</b>	<b>6</b>	<b>13</b>	<b>61</b>	<b>2</b>	<b>286</b>	<b>373</b>



**Figure 6.12** Distribution of staging for prostate cancer of region, 2022.

**Table 6.14** Distribution of staging for liver cancer of region, 2022.

Region	Staging							
	Stage 0	Stage I	Stage II	Stage III	Stage IV	Recurrent	Unknown	Total
Bangkok	0	0	1	0	29	1	96	127
North	0	0	1	0	2	0	4	7
Northeast	0	0	0	0	3	0	20	23
Central	1	1	2	2	22	0	73	101
East	0	1	1	1	5	0	15	23
West	0	0	0	0	4	0	8	12
South	0	0	0	0	4	0	10	14
<b>Total</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>3</b>	<b>69</b>	<b>1</b>	<b>226</b>	<b>307</b>



**Figure 6.13** Distribution of staging for liver cancer of region, 2022.

<b>Title</b>	<b>Ramathibodi Cancer Report 2022</b>
<b>Editorial Board</b>	<b>Assoc. Prof. Ekaphop Sirachainan</b> <b>Chairman of Ramathibodi Comprehensive Cancer Center</b>  <b>Prof. Sarikapan Wilailak</b> <b>Chairman of Ramathibodi Cancer Registry</b>  <b>Nintita Sripaiboonkij Thokanit, Dr.PH</b> <b>Ramathibodi Comprehensive Cancer Center</b>
<b>Published by</b>	<b>Ramathibodi Tumor Registry: A subsidiary of Ramathibodi</b> <b>Comprehensive Cancer Center, Ramathibodi Hospital</b> <b>270 Rama VI Road, Ratchatewi, Bangkok, Thailand 10400</b> <b>Tel. &amp; Fax. : +66 22010049, +66 22012682</b>
<b>Published</b>	<b>2023</b>
<b>Edition</b>	<b>1<sup>st</sup> edition</b>
<b>Physical</b>	<b>92 Pages</b>
<b>ISBN (e-book)</b>	<b>978-616-443-860-6</b>



**Published by Ramathibodi Tumor Registry:  
A subsidiary of Ramathibodi Comprehensive Cancer Center**

Faculty of Medicine Ramathibodi Hospital Mahidol University

Tel: 0-2201-2682, 0-2201-0049 Fax: 0-2201-2682

[https://www.rama.mahidol.ac.th/cancer\\_center](https://www.rama.mahidol.ac.th/cancer_center)